Original Article
Levodopa and the Progression of Parkinson's Disease
N Engl J Med 2004; 351:2498-2508December 9, 2004
- Abstract
Background
Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's disease.
Methods
In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa–levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or 150 and 600 mg, respectively, or a matching placebo for a period of 40 weeks, and then to undergo withdrawal of treatment for 2 weeks. The primary outcome was a change in scores on the Unified Parkinson's Disease Rating Scale (UPDRS) between baseline and 42 weeks. Neuroimaging studies of 142 subjects were performed at baseline and at week 40 to assess striatal dopamine-transporter density with the use of iodine-123–labeled 2-β-carboxymethoxy-3-β-(4-iodophenyl)tropane ([123I]β-CIT) uptake.
Results
The severity of parkinsonism increased more in the placebo group than in all the groups receiving levodopa: the mean difference between the total score on the UPDRS at baseline and at 42 weeks was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those receiving 300 mg daily, and –1.4 in those receiving 600 mg daily (P<0.001). In contrast, in a substudy of 116 patients the mean percent decline in the [123I]β-CIT uptake was significantly greater with levodopa than placebo (–6 percent among those receiving levodopa at 150 mg daily, –4 percent in those receiving it at 300 mg daily, and –7.2 percent among those receiving it at 600 mg daily, as compared with –1.4 percent among those receiving placebo; 19 patients with no dopaminergic deficits on the baseline scans were excluded from the analysis) (P=0.036). The subjects receiving the highest dose of levodopa had significantly more dyskinesia, hypertonia, infection, headache, and nausea than those receiving placebo.
Conclusions
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease. In contrast, the neuroimaging data suggest either that levodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter. The potential long-term effects of levodopa on Parkinson's disease remain uncertain.
Media in This Article
Figure 1
Random Assignments to Treatment, Completion of the Trial, and Reasons for Not Completing It.Figure 2
Changes in Total Scores on the Unified Parkinson's Disease Rating Scale (UPDRS) from Baseline through Evaluation at Week 42.Article Activity
- Article
Parkinson's disease is a progressively disabling neurodegenerative disorder that is manifested clinically by bradykinesia, tremor, rigidity, flexed posture, postural instability, and freezing of gait. It is characterized pathologically by the loss of pigmented dopaminergic neurons in the substantia nigra. The course of the clinical decline parallels that of the progressive degeneration of the remaining dopaminergic neurons.1 The use of levodopa as dopamine-replacement therapy is highly effective in ameliorating the symptoms of the disease and remains the standard drug with which other therapies are compared.2,3
Because levodopa and dopamine can generate reactive oxygen species and induce the degeneration of cultured dopamine neurons, concern has been raised that levodopa could enhance oxidative stress and hasten the degeneration of residual dopamine neurons in patients with Parkinson's disease.4-6 However, levodopa is not toxic in animals and may be trophic and promote the functional recovery of damaged nigral neurons.7-10 Humans without Parkinson's disease who are exposed to levodopa do not develop nigral damage,11,12 but such persons do not have increased oxidative stress in their substantia nigra neurons.
Whether levodopa is detrimental, beneficial, or without effect on the rate of the progression of Parkinson's disease is unknown and extremely important, both scientifically and clinically. We therefore conducted a controlled clinical trial to assess the effect of levodopa on the course of Parkinson's disease.
Methods
Study Design
Our multicenter, placebo-controlled, randomized, dose-ranging, double-blind clinical trial, called the Earlier versus Later Levodopa Therapy in Parkinson Disease (ELLDOPA) study, was conceived, organized, and implemented by the Parkinson Study Group and sponsored by the National Institute of Neurological Disorders and Stroke. The Department of Defense sponsored the single-photon-emission computed-tomography (SPECT) substudy. The subjects were enrolled between September 1998 and August 2001 at 33 sites in the United States and 5 sites in Canada. The study was approved by the institutional review boards at the participating sites, and all subjects gave written informed consent. An independent safety monitoring committee monitored the data, subjects' safety, and the tolerability of the study drug. There was no prespecified formal guideline for recommending either modification or termination of the trial.
Subjects
The subjects were 30 years of age or older, had received a diagnosis of Parkinson's disease within the past two years, had a rating on the modified Hoehn–Yahr scale13,14 of less than stage 3 (with stage 1 indicating unilateral disease, stage 2 mild bilateral disease, and stage 3 more advanced bilateral disease), and were considered not likely to require therapy for symptoms of the disease within the nine months after enrollment in the study. Patients were excluded if they were receiving antiparkinson medication, had been exposed to levodopa or to any dopamine agonist for more than 14 days, had an identifiable cause of parkinsonism, or had a tremor in any limb that was given a score of 3 or more on the Unified Parkinson's Disease Rating Scale (UPDRS),14 freezing of gait, loss of postural reflexes, major depression, or dementia.
Potential subjects were informed that only the assigned study drug would be permitted during the nine months of the study and that if they needed additional antiparkinson medication during this period, they would have to withdraw from the study. Subjects were randomly assigned to receive placebo or carbidopa–levodopa at a dose of 12.5 and 50 mg three times daily, 25 and 100 mg three times daily, or 50 and 200 mg three times daily, respectively. The doses were increased to the full amount over a period of nine weeks in a blinded fashion.
After 40 weeks, the subjects underwent a 3-day period of step-down withdrawal from the study drug. After two weeks without the study drug, a final assessment of the severity of the symptoms of Parkinson's disease was made. The selection of the 2-week duration for the washout period was based on reports that withdrawal from levodopa for a period up to 14 days resulted in a worsening of parkinsonism mainly within the first 7 days, with nonsignificant worsening beyond that point.15-17
Clinical Evaluation
The treating investigator, who was blinded to the treatment assignment, performed a clinical evaluation with the use of the UPDRS14 at the screening, baseline, and interim visits (at the end of weeks 3, 9, 24, and 40) and during each of the two weeks of the washout phase. During the four interim visits, the evaluations were performed before the administration of the first dose of the study drug. At every visit the treating investigator inquired about adverse events. The primary rater, who was also blinded to the treatment assignment and was kept unaware of information obtained during the course of the study, performed the examination with the use of the UPDRS only at the baseline evaluation, which took place within four weeks after screening, and again at the final evaluation, two weeks after the subject had undergone complete withdrawal from the study treatment (week 42). The study coordinators and the subjects also were blinded to the treatment assignments. An emergency unblinding procedure was established but was never used.
Outcome
The prespecified primary outcome was the change in the severity of parkinsonism between the baseline visit and week 42, as measured with the use of the total score on the UPDRS that was obtained by the primary rater; week 42 was 14 days after the withdrawal of the study drug. The expected result was a dose-related deterioration during washout if levodopa were shown to hasten the progression of Parkinson's disease. The change in the total scores on the UPDRS measured by the treating investigator at each visit was a prespecified secondary outcome. The treating investigator assessed adverse events with the use of open-ended questioning at each visit.
Substudy
After the clinical trial was begun, we conducted a substudy with the use of SPECT to measure striatal dopamine-transporter density with the use of iodine-123–labeled 2-β-carboxymethoxy-3-β-(4-iodophenyl)tropane ([123I]β-CIT). The methods have been reported previously.18 The subjects who gave consent underwent SPECT imaging just before the baseline visit and then again before the visit at week 40. The imaging studies were performed at that point rather than after the subjects had undergone withdrawal from levodopa, at week 42, because it was thought that the subjects would not be able to tolerate the procedure (including the necessary travel) after the return of parkinsonism or after its worsening. Another reason was that there was no clear evidence of a short-term effect of levodopa on dopamine-transporter imaging.
All imaging studies were performed at Yale University or the Institute for Neurodegenerative Disorders (both in New Haven, Connecticut). The neuroimaging personnel were blinded to the treatment assignment of the subjects. The results of the SPECT studies were transferred to and analyzed by the biostatistics center of the Parkinson Study Group. The prespecified outcome was the percent change in the ratio of the specific striatal [123I]β-CIT uptake to the nondisplaceable striatal [123I]β-CIT uptake between the two images.
Statistical Analysis
Allowing for a dropout rate of 10 percent of the subjects enrolled, we chose a sample size of 360 subjects (i.e., 90 subjects in each of the four treatment groups) in order to provide the study with 85 percent power to detect a dose–response relationship (linear trend) between the assigned doses and the change in the subjects' total score on the UPDRS between the baseline visit and the final visit at week 42. On the basis of the results of one study,19 we anticipated a rate of worsening in the total score on the UPDRS in the placebo group of 9.5 units over the 9.5 months of the study. The study was powered to detect a linear trend that corresponded to a 4-unit difference (45 percent of 9.5 units) in the score on the UPDRS between the highest dose of levodopa (600 mg per day) and placebo — that is, a change of either 13.5 or 5.5 units from baseline in the group receiving the highest dose of the active study drug.
The primary statistical tests were two-tailed, with an alpha level of 0.05. Only subjects who completed the two-week washout phase were included in this analysis. We used the intention-to-treat principle in the analysis, even if among some subjects the dose of the study drug were to be reduced during the study. The primary analysis assessed the dose–response relationship between the assigned doses and the worsening of parkinsonism, as indicated by the changes in the total score on the UPDRS between the baseline visit and week 42. Statistical comparisons were made by analysis of covariance in a model that adjusted for differences among the investigators performing the evaluations and in baseline values.
Results
Subjects
Of a total of 361 subjects enrolled in the study, 317 (88 percent) took the study medication for 40 weeks, and 311 (86 percent) completed the 2 weeks of washout (Figure 1Figure 1
Random Assignments to Treatment, Completion of the Trial, and Reasons for Not Completing It.). The neuroimaging substudy was begun after the enrollment of the first 108 subjects. Of the 253 subjects subsequently enrolled, 142 (56 percent) participated in the substudy and underwent the baseline SPECT. Of these, 135 (95 percent) returned for scanning at week 40. The demographic and clinical characteristics of the subjects in the treatment groups were similar at baseline, both in the entire sample and in the neuroimaging substudy (Table 1Table 1
Baseline Characteristics of the Study Subjects.).Clinical Outcome
Levodopa, in a dose–response pattern, significantly (P<0.001) reduced the worsening of symptoms of Parkinson's disease as reflected in the change between the total score on the UPDRS at baseline and that at week 42 (i.e., two weeks after washout of the study medication), as compared with the change in the placebo group (Figure 2Figure 2
Changes in Total Scores on the Unified Parkinson's Disease Rating Scale (UPDRS) from Baseline through Evaluation at Week 42. and Table 2Table 2
Changes in the Scores on the UPDRS between Baseline and Week 42.). The subjects in the placebo group had mild improvement at the week 3 visit, but after that their symptoms worsened steadily throughout the balance of the study period, including the two-week washout phase. A strong dose–response benefit was detected during the period in which the medication was administered beginning at week 9, when the full dose of 600 mg daily was reached in the group receiving the highest dose of levodopa, and it persisted through week 40. The scores on the UPDRS in the three levodopa groups worsened during the two-week washout period, but these groups did not deteriorate to the level observed in the placebo group, and the group receiving the highest dose of levodopa had the best result (Figure 2 and Table 2). The adverse events that were significantly more common among those receiving levodopa at 600 mg daily than in the placebo group were dyskinesias, nausea, infection, hypertonia, and headache (Table 3Table 3
Adverse Events.).Spect and [123I]β-CIT Substudy
The mean [123I]β-CIT uptake in the striatum, caudate, and putamen at baseline was consistent with values previously reported for patients with early Parkinson's disease.20 The percent decrease in striatal [123I]β-CIT uptake over the 40 weeks of the study treatment was greater among subjects in the levodopa groups than in the placebo group, but this difference was not statistically significant (Table 4Table 4
Change in Striatal [123I]β-CIT Uptake between Baseline and Week 40.). However, 21 of the 142 subjects (14.7 percent) had a putaminal [123I]β-CIT uptake of more than 3.25 at baseline (i.e., more than 75 percent of the age-expected putaminal uptake).21 An analysis of the results of SPECT after the exclusion of the 19 subjects without a dopaminergic deficit who returned for the neuroimaging study at week 40 showed a significantly greater decrease in [123I]β-CIT uptake among those receiving levodopa than among those receiving placebo (P=0.036) (Table 4).Discussion
We found no clinical evidence that levodopa accelerated the worsening of Parkinson's disease over the 9.5 months of observation. Rather, levodopa was associated with less worsening of parkinsonism than was placebo, consistent with the notion that it slows disease progression (Table 2 and Figure 2). In comparison with the scores on the UPDRS at baseline, the final scores, after the washout phase, had worsened by approximately 8 units in the placebo group, whereas the group receiving levodopa at 600 mg daily did not have evidence of deterioration. The groups receiving levodopa at lower doses did have deterioration, as shown by a comparison of their scores at baseline and at week 42, but the deterioration was less than in the placebo group (P<0.001).
We need to consider that a two-week washout from levodopa may have been insufficient to eliminate fully the effect of the medication on symptoms, and the results observed may be related to a profound effect of levodopa on symptoms that persists for a long time after the drug has been withdrawn. Indeed, Hauser and Holford,22 using a modeling technique, analyzed the withdrawal of levodopa in 20 patients and reported that the mean half-life of levodopa as measured by the loss of the clinical benefit was 7.9 days (95 percent confidence interval, 2.2 to 30.4 days). They suggest that a washout period of 32 days (four half-lives) may be required to eliminate 90 percent of the drug's effects on symptoms. However, we saw little deterioration after one week of washout. Near the end of the study, with the approval of the institutional review boards and of the National Institutes of Health, we asked the last 38 subjects remaining in the study to extend the washout period to four weeks. Among these subjects there was no further worsening of the scores on the UPDRS during the additional two weeks, but the small number of subjects renders this component of the study difficult to interpret.
Muenter and Tyce23 described motor responses with two types of duration, short and long, with levodopa therapy. The short-duration benefit lasts for a few hours after a single dose, and the long-duration benefit lasts several days. In our study, the long-duration benefit appears to have lasted approximately one to two weeks (Figure 2). To argue that a longer washout period might have revealed more clinical worsening than was observed, one could propose a hitherto unknown third type of duration of motor response, one that is more sustained than the so-called long-duration benefit. Such an enduring benefit could be envisioned to result from a prolonged pharmacodynamic effect, for example, on dopamine receptors.
If, however, the clinical effects observed offer evidence of neuroprotection, how can we explain the greater loss of dopamine transporter shown in the SPECT imaging studies of the subjects who received levodopa, as compared with those who received the placebo — a result that suggests the possibility of a levodopa-induced toxic effect on dopamine neurons? At the end of the study, when the SPECT neuroimaging studies were performed, the subjects were still taking levodopa, so it is possible to assume that levodopa has a pharmacologic effect on the dopamine transporter that interferes with and reduces the binding of the β-CIT ligand.
Indeed, one study found a reduction in dopamine-transporter binding with the use of positron-emission tomography (PET) and another dopamine-transporter ligand in patients with early Parkinson's disease who were treated for six weeks with levodopa at 300 mg daily.24 However, the sample size in this study, as in others that have shown no change in dopamine-transporter binding after short-term treatment with levodopa,25-27 was too small to demonstrate a statistically significant difference between levodopa and placebo. Further indirect support for the absence of a pharmacologic effect of levodopa on imaging studies of the dopamine transporter in the present study was the absence of decline in the [123I]β-CIT uptake by week 40 among the 16 subjects who received levodopa and whose SPECT scans were normal at baseline (i.e., without evidence of a dopaminergic deficit) (data not shown). However, in the absence of studies with larger samples and a longer period of treatment with levodopa, we cannot exclude the possibility that levodopa may simply down-regulate the dopamine transporter. Another consideration is that the falling dopamine concentration in the placebo group may have led to a compensatory increase in the activity of the dopamine transporter that could have increased [123I]β-CIT binding, but evidence for such an interpretation is lacking.
If levodopa has neuroprotective effects, what mechanisms could account for this property? In low concentrations and in the presence of glial cells, levodopa protects cultured dopaminergic neurons28-31 and up-regulates antioxidant and antiapoptotic proteins.29,32 Furthermore, in vivo studies suggest that levodopa can promote survival and enhance the sprouting of nigral dopamine neurons in rodents treated with the toxin 6-hydroxydopamine.9,10 The question of whether levodopa has a protective or a toxic effect in Parkinson's disease — reflecting the results of clinical examination and neuroimaging studies, respectively — cannot be answered with certainty, and future studies will be needed.
This dose–response, placebo-controlled clinical trial evaluating the effect of levodopa in patients with early Parkinson's disease showed a strikingly impressive dose–response clinical benefit: the higher the dose, the stronger and more lasting the benefit, and the benefit was greater even after the drug was withdrawn (Figure 2).
During withdrawal, we did not encounter the neuroleptic malignant-like effect (i.e., high fever, obtundation, and rigidity) that can occur with the sudden withdrawal of levodopa.33,34 Its absence may be related to the down-titration procedure employed; however, this complication is so rare that it might not have occurred in a study of this size even had levodopa been withdrawn suddenly, particularly in patients with early-stage disease.
Our study calls into question interpretations of the functional neuroimaging of the dopamine system. It has generally been assumed that imaging studies performed with 18F-fluorodopa PET and [123I]β-CIT SPECT can provide reliable information on the integrity of the nigrostriatal dopamine pathway. Our study and other recent clinical trials25,35 raise the possibility of a pharmacologic influence of dopaminergic therapy on these neuroimaging targets and point to the need for clarification of this issue.
Although the absence of evidence of a dopaminergic deficit in the imaging in our study and two other studies25,35 may simply represent a limitation of the sensitivity of the imaging techniques, the scans without a dopaminergic deficit raise doubt about whether the subjects had Parkinson's disease.35 In our study, the subjects with such scans at baseline had no worsening of the [123I]β-CIT uptake at week 40 (data not shown), nor did subjects with such scans in the group receiving the highest dose of levodopa have an improvement in the scores on the UPDRS (i.e., a change between the score at baseline and at week 40 of 3.38±4.25 units, as compared with a change of –4.95±10.4 units in the subjects receiving levodopa at 600 mg daily whose baseline SPECT scans showed abnormalities; P=0.002). Whether the subjects with no evidence of dopaminergic deficit on scanning do or do not have classic Parkinson's disease remains uncertain. The fact that scans of some patients with early Parkinson's disease do not have evidence of a dopaminergic deficit needs to be taken into consideration in the planning of future trials to test drugs for neuroprotective effects.
Finally, even though we cannot reconcile the clinical and imaging findings in our study, we can assure both patients with early Parkinson's disease and their physicians that, from a clinical perspective, our study did not find that levodopa hastens the progression of Parkinson's disease. On the basis of the study, we can recommend that the doses of levodopa be adjusted to fit the needs of the patient. Small doses were found to be effective, although less so than higher doses. High doses, however, were associated with a greater frequency of adverse events such as dyskinesia. For the present, until more evidence is available, we recommend customizing the dose of levodopa to the needs of the individual patient on the basis of the clinical response and the profile of adverse events.
Supported by grants from the National Institute of Neurological Disorders and Stroke (NS34796, to Dr. Fahn), the Department of Defense (DAMD 17-99-1-9472, to Dr. Marek), and the General Clinical Research Center of the National Center for Research Resources, National Institutes of Health (MO1-RR-00044 and MO1-RR-02066). Carbidopa–levodopa tablets and the matching placebo tablets were kindly provided by Teva Pharmaceuticals (Israel).
Drs. Fahn, Oakes, Shoulson, Kieburtz, Lang, Tanner, and Marek report having served as unpaid consultants to Teva Pharmaceuticals, and Dr. Olanow reports having served as a paid consultant to Teva Pharmaceuticals. Drs. Marek and Seibyl have an equity interest in Molecular Neuroimaging (New Haven), which carried out the [123I]β-CIT SPECT imaging for this study.
We are indebted to the subjects for their participation in the study; to K. Hyland (Baylor Medical College, Houston) for the independent, blinded chemical analyses of the contents of the tablets conducted annually to ascertain the chemical stability of levodopa and carbidopa; to S. Bennett, A. Brocht, D. Graffrath, J. Janciuras, C. Orme, L. Preston, K. Rothenburgh, C. Weaver, and A. Watts of the Biostatistics and Coordination Centers at the University of Rochester, Rochester, N.Y.; to the Independent Safety Monitoring Committee (P. Tariot, chair, Monroe Community Hospital, Rochester, N.Y.; to W.J. Hall, University of Rochester; to R. Rodnitzky, University of Iowa, Iowa City); to the National Institute of Neurological Disorders and Stroke Safety Monitoring Committee (E.C. Haley, chair, University of Virginia, Charlottesville; D. Eidelberg, North Shore University Medical Center, Manhasset, N.Y.; C.A. Gatsonis, Brown University, Providence, R.I.; W. Rocca, Mayo Clinic, Rochester, Minn.); and to E.J. Oliver (administrator), National Institute of Neurological Disorders and Stroke, Bethesda, Md.
Source Information
The writing committee of the Earlier versus Later Levodopa study (Stanley Fahn, M.D., Columbia University, New York; David Oakes, Ph.D., Ira Shoulson, M.D., Karl Kieburtz, M.D., and Alice Rudolph, Ph.D., University of Rochester, Rochester, N.Y.; Anthony Lang, M.D., Toronto Western Hospital, Toronto; C. Warren Olanow, M.D., Mount Sinai School of Medicine, New York; Caroline Tanner, M.D., Ph.D., the Parkinson's Institute, Sunnyvale, Calif.; and Kenneth Marek, M.D., Institute for Neurodegenerative Disorders, New Haven, Conn.) takes responsibility for the content of this article.
Address reprint requests to Dr. Stanley Fahn at the Neurological Institute, 710 W. 168th St., New York, NY 10032-3784, or at fahn@neuro.columbia.edu.
The investigators and coordinators of the Parkinson Study Group are listed in the Appendix.
Appendix
The following members of the Parkinson Study Group participated in the Earlier versus Later Levodopa Therapy in Parkinson Disease (ELLDOPA) study and contributed to this report. Steering committee: S. Fahn, principal investigator, Columbia University, New York; D. Oakes, chief biostatistician; I. Shoulson, coprincipal investigator; K. Kieburtz, director, Clinical Trials Coordination Center; A. Rudolph, senior project coordinator, University of Rochester, Rochester, N.Y.; K. Marek, neuroimager; J. Seibyl, neuroimager, Institute for Neurodegenerative Disorders, New Haven, Conn.; A. Lang, Toronto Western Hospital, Toronto; C.W. Olanow, Mount Sinai School of Medicine, New York; C. Tanner, The Parkinson's Institute, Sunnyvale, Calif.; G. Schifitto, medical monitor, University of Rochester, Rochester, N.Y.; H. Zhao, biostatistician, University of Rochester, Rochester, N.Y.; L. Reyes, administrator, Columbia University, New York; A. Shinaman, administrator, University of Rochester, Rochester, N.Y.; Participating primary raters, treating investigators, and coordinators: Rush–Presbyterian–St. Luke's Medical Center, Chicago: C. Comella, C. Goetz, L. Blasucci; Barrow Neurological Institute, Phoenix, Ariz.: J. Samanta, M. Stacy, K. Williamson, M. Harrigan; Columbia University, New York: P. Greene, B. Ford, C. Moskowitz; Parkinson's and Movement Disorder Institute, Fountain Valley, Calif.: D. Truong, M. Pathak; Baylor College of Medicine, Houston: J. Jankovic, W. Ondo, F. Atassi, C. Hunter; Brown University, Providence, R.I.: C. Jacques, J.H. Friedman, M. Lannon; Institute for Neurodegenerative Disorders, New Haven, Conn.: D.S. Russell, D. Jennings, B. Fussell; Massachusetts General Hospital, Boston: D. Standaert, M.A. Schwarzschild, J. Growdon, M. Tennis; McGill Centre for Studies in Aging, Verdun, Que., Canada: S. Gauthier, M. Panisset, J. Hall; Oregon Health and Science University, Portland: S. Gancher, J. Hammerstad, C. Stone, B. Alexander-Brown; Albany Medical College, Albany, N.Y.: S. Factor, E. Molho, D. Brown (deceased), S. Evans; Scott and White Hospital–Texas A&M University, Temple: J. Clark, B. Manyam, P. Simpson, B. Wulbrecht, J. Whetteckey; University of Alberta, Edmonton, Canada: W. Martin, T. Roberts, P. King; University of South Florida, Tampa: R. Hauser, T. Zesiewicz, L. Gauger; University of Virginia, Charlottesville: J. Trugman, G.F. Wooten, E. Rost-Ruffner; Washington University, St. Louis: J. Perlmutter, B. Racette; University of Calgary, Alta., Canada: O. Suchowersky, R. Ranawaya, S. Wood, C. Pantella; University of Rochester, Rochester, N.Y.: R. Kurlan, I. Richard, N. Pearson; Mayo Clinic, Scottsdale, Ariz.: J. Caviness, C. Adler, M. Lind; University of Pennsylvania, Philadelphia: T. Simuni, A. Siderowf, A. Colcher, M. Lloyd; University of Miami, Miami: W. Weiner, L. Shulman, W. Koller, K. Lyons; Boston University, Boston: R. Feldman (deceased), M.-H. St.-Hilaire, S. Ellias, C.-A. Thomas; Emory University, Atlanta: J. Juncos, R. Watts, A. Partlow; The Parkinson's Institute, Sunnyvale, Calif.: J. Tetrud, D.M. Togasaki, M. Welsh, T. Stewart; University of Medicine and Dentistry of New Jersey–Robert Wood Johnson, New Brunswick: M.H. Mark, J.I. Sage, D. Caputo; Louisiana State University, New Orleans: H. Gould, J. Rao, A. McKendrick; Mount Sinai School of Medicine, New York: M. Brin, F. Danisi, R. Benabou; Ohio State University, Columbus: J. Hubble, G. Paulson, C. Reider; Toronto Western Hospital, Toronto: A. Birnbaum, J. Miyasaki, L. Johnston, J. So; University of Kansas, Kansas City: R. Pahwa, R. Dubinsky; Mayo Clinic, Jacksonville, Fla.: Z. Wszolek, R. Uitti, M. Turk; Minneapolis Veterans Affairs Hospital, Minneapolis: P. Tuite, D. Rottenberg, J. Hansen; University of Puerto Rico, San Juan: C. Serrano Ramos; University of Southern California, Los Angeles: C. Waters, M. Lew, M. Welsh, C. Kawai; Colorado Neurological Institute, Englewood: C. O'Brien, R. Kumar, L. Seeberger, D. Judd; Ottawa Civic Hospital, Ottawa: T. Mendis, C.L. Barclay, D.A. Grimes, L. Sutherland; Johns Hopkins University, Baltimore: T. Dawson, S. Reich, R. Dunlop; University of Michigan, Ann Arbor: R. Albin, K. Frey, K. Wernette.
- References
References
1
Riederer P ,Wuketich S . Time course of nigrostriatal degeneration in Parkinson's disease: a detailed study of influential factors in human brain amine analysis. J Neural Transm 1976;38:277-301
CrossRef | Web of Science | Medline2
Practice parameters: initial therapy of Parkinson's disease (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1993;43:1296-1297
Web of Science | Medline3
Fahn S . Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999;56:529-535
CrossRef | Web of Science | Medline4
Fahn S . Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997;8:376-393
CrossRef | Web of Science5
Fahn S . Is levodopa toxic? Neurology 1996;47:Suppl 3:S184-S195
Web of Science | Medline6
Barzilai A ,Melamed E ,Shirvan A . Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease? Cell Mol Neurobiol 2001;21:215-235
CrossRef | Web of Science | Medline7
Mytilineou C ,Walker RH ,JnoBaptiste R ,Olanow CW . Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003;304:792-800
CrossRef | Web of Science | Medline8
Agid Y . Levodopa: is toxicity a myth? Neurology 1998;50:858-863
Web of Science | Medline9
Murer MG ,Dziewczapolski G ,Menalled LB , et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575
CrossRef | Web of Science | Medline10
Datla KP ,Blunt SB ,Dexter DT . Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl (3) nigrostriatal lesions. Mov Disord 2001;16:424-434
CrossRef | Web of Science | Medline11
Quinn N ,Parkes D ,Janota I ,Marsden CD . Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68
CrossRef | Medline12
Rajput AH ,Fenton ME ,Birdi S ,Macaulay R . Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638
CrossRef | Web of Science | Medline13
Hoehn MM ,Yahr MD . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
Web of Science | Medline14
Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, N.J.: Macmillan Healthcare Information, 1987:153-163, 293-304.
15
Cotzias GC ,Van Woert MH ,Schiffer LM . Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379
Full Text | Web of Science | Medline16
Hauser RA ,Koller WC ,Hubble JP ,Malapira T ,Busenbark K ,Olanow CW . Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2000;15:485-489
CrossRef | Web of Science | Medline17
Olanow CW ,Hauser RA ,Gauger L , et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777
CrossRef | Web of Science | Medline18
Marek K ,Innis R ,van Dyck C , et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094
Web of Science | Medline19
Parkinson Study Group
Full Text | Web of Science | Medline20
Seibyl JP ,Marek KL ,Quinlan D , et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598
CrossRef | Web of Science | Medline21
Marek K, Seibyl J, Parkinson Study Group
CrossRef22
Hauser RA ,Holford NHG . Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002;17:961-968
CrossRef | Web of Science | Medline23
Muenter MD ,Tyce GM . L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239
Web of Science | Medline24
Guttman M ,Stewart D ,Hussey D ,Wilson A ,Houle S ,Kish S . Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-1564
Web of Science | Medline25
Parkinson Study Group
CrossRef | Web of Science26
Innis RB ,Marek KL ,Sheff K , et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999;14:436-442
CrossRef | Web of Science | Medline27
Nurmi E ,Bergman J ,Eskola O , et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [F-18]CFT PET study. J Cereb Blood Flow Metab 2000;20:1604-1609
CrossRef | Web of Science | Medline28
Mytilineou C ,Han SK ,Cohen G . Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993;61:1470-1478
CrossRef | Web of Science | Medline29
Mena MA ,Casarejos MJ ,Carazo A ,Paino CL ,Garcia de Yebenes J . Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 1997;104:317-328
CrossRef | Web of Science | Medline30
Mena MA ,Davila V ,Sulzer D . Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408
CrossRef | Web of Science | Medline31
Desagher S ,Glowinski J ,Premont J . Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996;16:2553-2562
Web of Science | Medline32
Han SK ,Mytilineou C ,Cohen G . L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510
CrossRef | Web of Science | Medline33
Friedman JH ,Feinberg SS ,Feldman RG . A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985;254:2792-2795
CrossRef | Web of Science | Medline34
Gordon PH ,Frucht SJ . Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;16:960-962
CrossRef | Web of Science | Medline35
Whone AL ,Watts RL ,Stoessl AJ , et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101
CrossRef | Web of Science | Medline
- Citing Articles (350)
Citing Articles
1
Ruiping Xia, Zhi-Hong Mao. (2012) Progression of motor symptoms in Parkinson’s disease. Neuroscience Bulletin 28:1, 39-48
CrossRef2
Alberto J Espay, Alfonso Fasano, Francesca Morgante. (2012) The six gaps in the search of neuroprotection for Parkinson’s disease. Expert Review of Neurotherapeutics 12:2, 111-113
CrossRef3
Heinz Reichmann, Murat Emre. (2012) Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone. Expert Review of Neurotherapeutics 12:2, 119-131
CrossRef4
Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti, Olivier Rascol. (2012) Rotigotine transdermal patch for the treatment of Parkinson’s Disease. Fundamental & Clinical Pharmacologyno-no
CrossRef5
S. Leucht, S. Hierl, W. Kissling, M. Dold, J. M. Davis. (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. The British Journal of Psychiatry 200:2, 97-106
CrossRef6
(2012) Temblor en el anciano. FMC - Formación Médica Continuada en Atención Primaria 19, 32-42
CrossRef7
John D. McCorvy, Val J. Watts, David E. Nichols. (2012) Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology
CrossRef8
O. Gershanik, P. Jenner. (2012) Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. European Journal of Neurologyno-no
CrossRef9
M.P. Zanin, L.N. Pettingill, A.R. Harvey, D.F. Emerich, C.G. Thanos, R.K. Shepherd. (2012) The development of encapsulated cell technologies as therapies for neurological and sensory diseases. Journal of Controlled Release
CrossRef10
W. Michael Caudle, Thomas S. Guillot, Carlos R. Lazo, Gary W. Miller. (2012) Industrial toxicants and Parkinson's disease. NeuroToxicology
CrossRef11
Perdita A. Cheshire, David R. Williams. (2012) Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease. Journal of Clinical Neuroscience
CrossRef12
Theresa A. Zesiewicz. (2011) Parkinson disease: The controversy of levodopa toxicity in Parkinson disease. Nature Reviews Neurology 8:1, 8-10
CrossRef13
Suwanna Setthawatcharawanich, Pornchai Sathirapanya, Kanitpong Phabphal, Kitti Limapichat. (2011) Short questionnaire for Parkinson's disease as a screening instrument. Clinical Neurology and Neurosurgery 113:10, 885-888
CrossRef14
F. Klostermann. (2011) Intestinal levodopa infusion and COMT inhibition - a promising link. European Journal of Neurologyno-no
CrossRef15
Pedro J. García-Ruiz, Javier del Val, Ignacio Mahillo Fernández, Antonio Herranz. (2011) What Factors Influence Motor Complications in Parkinson Disease?. Clinical Neuropharmacology1
CrossRef16
Isabel Ybot-Gorrin, Francisco Vivancos-Matellano, José Rafael Chacón-Peña, Hortensia Alonso-Navarro, Félix Javier Jiménez-Jiménez. (2011) Assessment of Parkinson Disease. The Neurologist 17, S21-S29
CrossRef17
Jeff A. Beeler. (2011) Preservation of function in Parkinson's disease: What's learning got to do with it?. Brain Research 1423, 96-113
CrossRef18
J. L. Cummings, C. Henchcliffe, S. Schaier, T. Simuni, A. Waxman, P. Kemp. (2011) The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134:11, 3146-3166
CrossRef19
Nina Schlede, Ronan Zimmermann, Michael M. Ehrensperger, Ute Gschwandtner, Martin Hardmeier, Florian Hatz, Andreas U. Monsch, Yvonne Naegelin, Peter Fuhr. (2011) Clinical EEG in cognitively impaired patients with Parkinson's Disease. Journal of the Neurological Sciences 310:1-2, 75-78
CrossRef20
Jan Booij, Henk W. Berendse. (2011) Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway. Journal of the Neurological Sciences 310:1-2, 40-43
CrossRef21
P.D. Charles, R.M. Dolhun, C.E. Gill, T.L. Davis, M.J. Bliton, M.G. Tramontana, R.M. Salomon, L. Wang, P. Hedera, F.T. Phibbs, J.S. Neimat, P.E. Konrad. (2011) Deep brain stimulation in early Parkinson’s disease: Enrollment experience from a pilot trial. Parkinsonism & Related Disorders
CrossRef22
Anthony H.V. Schapira. (2011) Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease. CNS Drugs1
CrossRef23
Zheng Zhou, Jun-Ming Liao, Peng Zhang, Jun-Bao Fan, Jie Chen, Yi Liang. (2011) Parkinson disease drug screening based on the interaction between D2 dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis. Protein & Cell 2:11, 899-905
CrossRef24
Mark F. Lew, Monique Somogyi, Kevin McCague, Mickie Welsh, on behalf of the LCE QoL Study Grou. (2011) Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off. International Journal of Neuroscience 121:11, 605-613
CrossRef25
Sandra W. Chan, Rachael A. Dunlop, Anthony Rowe, Kay L. Double, Kenneth J. Rodgers. (2011) l-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro. Experimental Neurology
CrossRef26
Tom Valeo. (2011) Is Levodopa Neurotoxic? New Data — and the Controversy Lives On. Neurology Today 11:19, 1
CrossRef27
Brigitte Spinnewyn, Christelle Charnet, Sylvie Cornet, Véronique Roubert, Pierre-Etienne Chabrier, Michel Auguet. (2011) An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats. Fundamental & Clinical Pharmacology 25:5, 608-618
CrossRef28
Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Movement Disorders 26:S3, S2-S41
CrossRef29
Nikolaos D. Papathanasiou, Anastasios Boutsiadis, John Dickson, Jamshed B. Bomanji. (2011) Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies. Parkinsonism & Related Disorders
CrossRef30
Éva M. Szegő, Ellen Gerhardt, Pawel Kermer, Jörg B. Schulz. (2011) A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. Neurobiology of Disease
CrossRef31
Chandler E. Gill, Laura A. Allen, Peter E. Konrad, Thomas L. Davis, Mark J. Bliton, Stuart G. Finder, Michael G. Tramontana, C. Chris Kao, Michael S. Remple, Courtney H. Bradenham, P. David Charles. (2011) Deep Brain Stimulation for Early-Stage Parkinson's Disease: An Illustrative Case. Neuromodulation: Technology at the Neural Interfaceno-no
CrossRef32
Robert A. Hauser, Aaron L. Ellenbogen, Leo Verhagen Metman, Ann Hsu, Martin J. O'Connell, Nishit B. Modi, Hsuan-Ming Yao, Sherron H. Kell, Suneel K. Gupta. (2011) Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Movement Disorders 26:12, 2246-2252
CrossRef33
Angelo Antonini, Pablo Martinez-Martin, Ray K. Chaudhuri, Marcelo Merello, Robert Hauser, Regina Katzenschlager, Per Odin, Mark Stacy, Fabrizio Stocchi, Werner Poewe, Oliver Rascol, Cristina Sampaio, Anette Schrag, Glenn T. Stebbins, Christopher G. Goetz. (2011) Wearing-off scales in Parkinson's disease: Critique and recommendations. Movement Disorders 26:12, 2169-2175
CrossRef34
Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong. (2011) Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa. Neuropsychopharmacology
CrossRef35
Elise Anderson, John Nutt. (2011) The long-duration response to levodopa: Phenomenology, potential mechanisms and clinical implications. Parkinsonism & Related Disorders 17:8, 587-592
CrossRef36
F.M. Skidmore, M. Yang, L. Baxter, K.M. von Deneen, J. Collingwood, G. He, K. White, D. Korenkevych, A. Savenkov, K.M. Heilman, M. Gold, Y. Liu. (2011) Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. NeuroImage
CrossRef37
Javier Ganz, Nirit Lev, Eldad Melamed, Daniel Offen. (2011) Cell replacement therapy for Parkinson’s disease: how close are we to the clinic?. Expert Review of Neurotherapeutics 11:9, 1325-1339
CrossRef38
F. Stocchi, J. M. Rabey. (2011) Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. European Journal of Neurologyno-no
CrossRef39
Janusz Lipski, Robert Nistico, Nicola Berretta, Ezia Guatteo, Giorgio Bernardi, Nicola B. Mercuri. (2011) l-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?. Progress in Neurobiology 94:4, 389-407
CrossRef40
Pedro J. Garcia-Ruiz. (2011) Gait disturbances in Parkinson disease. Did freezing of gait exist before levodopa? Historical review. Journal of the Neurological Sciences 307:1-2, 15-17
CrossRef41
Claire Henchcliffe, W. Lawrence Severt. (2011) Disease Modification in Parkinsonʼs Disease. Drugs & Aging 28:8, 605-615
CrossRef42
David J. Brooks, Nicola Pavese. (2011) Imaging biomarkers in Parkinson's disease. Progress in Neurobiology
CrossRef43
C. Warren Olanow, Fabrizio Stocchi, Anthony E. Lang. 2011. The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease. , 1-6.
CrossRef44
Joo Yeon Lee, Jogarao V. S. Gobburu. (2011) Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development. The AAPS Journal
CrossRef45
Martin Bareš, Irena Rektorová, Robert Jech, Kateřina Farníková, Jan Roth, Evžen Růžička, Petr Kaňovský, Ivan Rektor, Tomáš Pavlík, Leona Uhlířová, Jaroslav Vydlák. (2011) Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?. Journal of Neural Transmission
CrossRef46
Deniz Kahraman, Carsten Eggers, Harald Schicha, Lars Timmermann, Matthias Schmidt. (2011) Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. Journal of Neurology
CrossRef47
Santiago Perez-Lloret, Olivier Rascol. (2011) Safety of rasagiline for the treatment of Parkinson's disease. Expert Opinion on Drug Safety 10:4, 633-643
CrossRef48
Bazoumana Ouattara, Laurent Grégoire, Marc Morissette, Fabrizio Gasparini, Ivo Vranesic, Graeme Bilbe, Donald R. Johns, Alex Rajput, Oleh. Hornykiewicz, Ali H. Rajput, Baltazar Gomez-Mancilla, Thérèse Di Paolo. (2011) Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiology of Aging 32:7, 1286-1295
CrossRef49
Julia Dorschner, Georgios Farmakis, Stefanie Behnke, Dirk Hellwig, Susanne Schneider, Klaus Fassbender, Carl-Martin Kirsch, Ulrich Dillmann, Jörg Spiegel. (2011) Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson’s disease. Parkinsonism & Related Disorders 17:5, 372-375
CrossRef50
Carl E. Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Keith Wheatley, Richard Gray. (2011) Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?. Movement Disorders 26:7, 1187-1193
CrossRef51
Olivier Rascol, Cheryl J Fitzer-Attas, Robert Hauser, Joseph Jankovic, Anthony Lang, J William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi, Eduardo Tolosa, Eli Eyal, Yoni M Weiss, C Warren Olanow. (2011) A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. The Lancet Neurology 10:5, 415-423
CrossRef52
Wassilios G. Meissner, Mark Frasier, Thomas Gasser, Christopher G. Goetz, Andres Lozano, Paola Piccini, José A. Obeso, Olivier Rascol, Anthony Schapira, Valerie Voon, David M. Weiner, François Tison, Erwan Bezard. (2011) Priorities in Parkinson's disease research. Nature Reviews Drug Discovery 10:5, 377-393
CrossRef53
C. Warren Olanow, Kathryn B. Wunderle, Karl Kieburtz. (2011) Milestones in movement disorders clinical trials: Advances and landmark studies. Movement Disorders 26:6, 1003-1014
CrossRef54
Olivier Rascol, Andres Lozano, Matthew Stern, Werner Poewe. (2011) Milestones in Parkinson's disease therapeutics. Movement Disorders 26:6, 1072-1082
CrossRef55
T. B. Sherer. (2011) Biomarkers for Parkinson's Disease. Science Translational Medicine 3:79, 79ps14-79ps14
CrossRef56
Livia Dézsi, László Vécsei. (2011) Parkinson’s disease: will therapy move beyond dopaminergic medication?. Clinical Investigation 1:3, 381-398
CrossRef57
Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray. (2011) Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Movement Disorders 26:4, 587-598
CrossRef58
Nick H. G. Holford, John G. Nutt. (2011) Interpreting the results of Parkinson's disease clinical trials: Time for a change. Movement Disorders 26:4, 569-577
CrossRef59
Raúl de la Fuente-Fernández, Silke Appel-Cresswell, Doris J Doudet, Vesna Sossi. (2011) Functional neuroimaging in Parkinson's disease. Expert Opinion on Medical Diagnostics 5:2, 109-120
CrossRef60
A. H. V. Schapira. (2011) Challenges to the development of disease-modifying therapies in Parkinson’s disease. European Journal of Neurology 18, 16-21
CrossRef61
Bart Post, Dino Muslimovic, Nan van Geloven, Johannes D. Speelman, Ben Schmand, Rob J. de Haan, . (2011) Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Movement Disorders 26:3, 449-456
CrossRef62
Richard W. Walker, Anna R. Howells, William K. Gray. (2011) The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism & Related Disorders 17:1, 27-29
CrossRef63
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Parkinsonism. , 66-92.
CrossRef64
Sabine Skodda, Andrea Flasskamp, Uwe Schlegel. (2011) Instability of syllable repetition as a marker of disease progression in Parkinson's disease: A longitudinal study. Movement Disorders 26:1, 59-64
CrossRef65
Ainhi D. Ha, Joseph Jankovic. 2011. An Introduction to Dyskinesia—The Clinical Spectrum. , 1-29.
CrossRef66
Dustin R. Wakeman, Hemraj B. Dodiya, Jeffrey H. Kordower. (2011) Cell Transplantation and Gene Therapy in Parkinson's Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:1, 126-158
CrossRef67
Mercedes Unzeta, Elisenda Sanz. 2011. Novel MAO-B inhibitors. , 217-236.
CrossRef68
Magdalena Hubbuch, Georgios Farmakis, Andrea Schaefer, Stefanie Behnke, Susanne Schneider, Dirk Hellwig, Klaus Fassbender, Carl-Martin Kirsch, Ulrich Dillmann, Joerg Spiegel. (2011) FP-CIT SPECT Does Not Predict the Progression of Motor Symptoms in Parkinson’s Disease. European Neurology 65:4, 187-192
CrossRef69
L.M. Chahine, M.B. Stern. 2011. Rasagiline in Parkinson's Disease. , 151-168.
CrossRef70
Sean S. O'Sullivan, Mary Johnson, David R. Williams, Tamas Revesz, Janice L. Holton, Andrew J. Lees, Elaine K. Perry. (2011) The effect of drug treatment on neurogenesis in Parkinson's disease. Movement Disorders 26:1, 45-50
CrossRef71
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Medical treatment of Parkinson disease. , 119-156.
CrossRef72
Jonathan R Evans, Roger A Barker. (2011) Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. Expert Opinion on Pharmacotherapy1
CrossRef73
Yvette M. Bordelon, Ron D. Hays, Stefanie D. Vassar, Natalie Diaz, Jeff Bronstein, Barbara G. Vickrey. (2011) Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease. Parkinson's Disease 2011, 1-6
CrossRef74
Michael A. Schwarzschild, Kenneth Marek, Shirley Eberly, David Oakes, Ira Shoulson, Danna Jennings, John Seibyl, Alberto Ascherio, . (2011) Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”. Movement Disordersn/a-n/a
CrossRef75
Kumar M Prakash, Eng-King Tan. (2010) Development of Parkinson’s disease biomarkers. Expert Review of Neurotherapeutics 10:12, 1811-1825
CrossRef76
Tiziana Alberio, Mauro Fasano. (2010) Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies. Journal of Biotechnology 156:4, 325-337
CrossRef77
Claire L. Tomlinson, Rebecca Stowe, Smitaa Patel, Caroline Rick, Richard Gray, Carl E. Clarke. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders 25:15, 2649-2653
CrossRef78
Mario Zappia, Carlo Colosimo, Werner Poewe. (2010) Levodopa: back to the future. Journal of Neurology 257:S2, 247-248
CrossRef79
John C. Morgan, Shyamal H. Mehta, Kapil D. Sethi. (2010) Biomarkers in Parkinson’s Disease. Current Neurology and Neuroscience Reports 10:6, 423-430
CrossRef80
Janis M. Miyasaki. (2010) Evidence-based initiation of dopaminergic therapy in Parkinson's disease. Journal of Neurology 257:S2, 309-313
CrossRef81
C. E. Clarke. (2010) Has drug therapy changed the natural history of Parkinson’s disease?. Journal of Neurology 257:S2, 262-267
CrossRef82
Alipi V. Naydenov, Fair Vassoler, Andrew S. Luksik, Joanna Kaczmarska, Christine Konradi. (2010) Mitochondrial abnormalities in the putamen in Parkinson’s disease dyskinesia. Acta Neuropathologica 120:5, 623-631
CrossRef83
E. Hametner, K. Seppi, W. Poewe. (2010) The clinical spectrum of levodopa-induced motor complications. Journal of Neurology 257:S2, 268-275
CrossRef84
Begoña Villar-Cheda, Jannette Rodríguez-Pallares, Rita Valenzuela, Ana Muñoz, Maria J. Guerra, Ovidiu C. Baltatu, Jose L. Labandeira-Garcia. (2010) Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson’s disease. European Journal of Neuroscience 32:10, 1695-1706
CrossRef85
W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder. 2010. Early (Uncomplicated) Parkinson's Disease. , 217-236.
CrossRef86
Torun Malmlöf, Daniella Rylander, Rudolf-Giesbert Alken, Frank Schneider, Torgny H. Svensson, M. Angela Cenci, Björn Schilström. (2010) Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Experimental Neurology 225:2, 408-415
CrossRef87
Sankar Surendran, Srinivasagam Rajasankar. (2010) Parkinson’s disease: oxidative stress and therapeutic approaches. Neurological Sciences 31:5, 531-540
CrossRef88
Jong-Min Kim, Ji Seon Kim, Ki Woong Kim, Seok Bum Lee, Joon Hyuk Park, Jung Jae Lee, Yu Kyeong Kim, Sang Eun Kim, Beom S. Jeon. (2010) Study of the prevalence of Parkinson's disease using dopamine transporter imaging. Neurological Research 32:8, 845-851
CrossRef89
David J Brooks. (2010) Imaging dopamine transporters in Parkinson’s disease. Biomarkers in Medicine 4:5, 651-660
CrossRef90
Andy Welch, Sally Pimlott. 2010. PET and SPECT in Drug Development. .
CrossRef91
Michele Tagliati, Caitlin Martin, Ron Alterman. (2010) Lack of Motor Symptoms Progression in Parkinson's Disease Patients With Long-Term Bilateral Subthalamic Deep Brain Stimulation. International Journal of Neuroscience 120:11, 717-723
CrossRef92
Xiaoming Shu, Guochun Wang, Xin Lu, Yao Xie. (2010) Rheumatoid-like deformities in Parkinson’s disease with 1-year follow-up: case report and literature review. Rheumatology International 30:11, 1493-1497
CrossRef93
S.J. Ortega Lozano, M.D. Martinez del Valle Torres, E. Ramos Moreno, S. Sanz Viedma, T. Amrani Raissouni, J.M. Jiménez-Hoyuela. (2010) Valoración cuantitativa del SPECT con FP-CIT. Importancia del área de referencia. Revista Española de Medicina Nuclear 29:5, 246-250
CrossRef94
J.C. Sharma, C.G. Bachmann, G. Linazasoro. (2010) Classifying risk factors for dyskinesia in Parkinson’s disease. Parkinsonism & Related Disorders 16:8, 490-497
CrossRef95
Barry J. Snow, Fiona L. Rolfe, Michelle M. Lockhart, Christopher M. Frampton, John D. O'Sullivan, Victor Fung, Robin A.J. Smith, Michael P. Murphy, Kenneth M. Taylor. (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Movement Disorders 25:11, 1670-1674
CrossRef96
S. Tsouli, S. Konitsiotis. (2010) How should we treat a patient with early Parkinson’s disease?. International Journal of Clinical Practice 64:9, 1210-1219
CrossRef97
N Holford, S C Ma, B A Ploeger. (2010) Clinical Trial Simulation: A Review. Clinical Pharmacology & Therapeutics 88:2, 166-182
CrossRef98
David Devos, L. Defebvre, R. Bordet. (2010) Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease. Fundamental & Clinical Pharmacology 24:4, 407-421
CrossRef99
Raúl de la Fuente-Fernández, Michael Schulzer, Edwin Mak, Vesna Sossi. (2010) Trials of neuroprotective therapies for Parkinson’s disease: Problems and limitations. Parkinsonism & Related Disorders 16:6, 365-369
CrossRef100
Mark Stacy. (2010) The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease. Journal of Neural Transmission 117:7, 837-846
CrossRef101
Xiu-Min Li, Hai-Bin Ma, Zhan-Qiang Ma, Lu-Fan Li, Chang-Liang Xu, Rong Qu, Shi-Ping Ma. (2010) Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine. Journal of Ethnopharmacology 130:1, 19-27
CrossRef102
Fabrizio Stocchi, Stefano Marconi. (2010) Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease. Clinical Neuropharmacology 33:4, 198-203
CrossRef103
Fabrizio Stocchi, Olivier Rascol, Karl Kieburtz, Werner Poewe, Joseph Jankovic, Eduardo Tolosa, Paulo Barone, Anthony E. Lang, C. Warren Olanow. (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Annals of Neurology 68:1, 18-27
CrossRef104
Christopher Kobylecki, M. Angela Cenci, Alan R. Crossman, Paula Ravenscroft. (2010) Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease. Journal of Neurochemistry 114:2, 499-511
CrossRef105
Yuen-Shan Ho, Kwok-Fai So, Raymond Chuen-Chung Chang. (2010) Anti-aging herbal medicine—How and why can they be used in aging-associated neurodegenerative diseases?. Ageing Research Reviews 9:3, 354-362
CrossRef106
Rajaraman Gnana Oli, Gholamreza Fazeli, Wilfried Kuhn, Susanne Walitza, Manfred Gerlach, Helga Stopper. (2010) No increased chromosomal damage in l-DOPA-treated patients with Parkinson’s disease: a pilot study. Journal of Neural Transmission 117:6, 737-746
CrossRef107
Karla Eggert, David Squillacote, Paolo Barone, Richard Dodel, Regina Katzenschlager, Murat Emre, Andrew J. Lees, Olivier Rascol, Werner Poewe, Eduardo Tolosa, Claudia Trenkwalder, Marco Onofrj, Fabrizio Stocchi, Giuseppe Nappi, Vladimir Kostic, Jagoda Potic, Evzen Ruzicka, Wolfgang Oertel, . (2010) Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Movement Disorders 25:7, 896-905
CrossRef108
Ray L. Watts, Kelly E. Lyons, Rajesh Pahwa, Kapil Sethi, Matthew Stern, Robert A. Hauser, Warren Olanow, Alex M. Gray, Bryan Adams, Nancy L. Earl, . (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Movement Disorders 25:7, 858-866
CrossRef109
Vanessa K. Hinson. (2010) Parkinson’s Disease and Motor Fluctuations. Current Treatment Options in Neurology 12:3, 186-199
CrossRef110
A. Jon Stoessl. (2010) Scans without evidence of dopamine deficiency: The triumph of careful clinical assessment. Movement Disorders 25:5, 529-530
CrossRef111
June-Hee Park, Grigori Enikolopov. (2010) Transient elevation of adult hippocampal neurogenesis after dopamine depletion. Experimental Neurology 222:2, 267-276
CrossRef112
Andre C. Felicio, Clecio Godeiro-Junior, Ming C. Shih, Vanderci Borges, Sônia M.A. Silva, Patrícia de Carvalho Aguiar, Marcelo Q. Hoexter, Orlando G.P. Barsottini, Luiz A.F. Andrade, Rodrigo A. Bressan, Henrique B. Ferraz. (2010) Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. Journal of the Neurological Sciences 291:1-2, 64-68
CrossRef113
Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione. (2010) Therapy for dyskinesias in Parkinson’s disease patients. Future Neurology 5:2, 277-299
CrossRef114
Valentina Berti, Cristina Polito, Silvia Ramat, Eleonora Vanzi, Maria Teresa Cristofaro, Giannantonio Pellicanò, Francesco Mungai, Paolo Marini, Andreas Robert Formiconi, Sandro Sorbi, Alberto Pupi. (2010) Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson’s disease. European Journal of Nuclear Medicine and Molecular Imaging 37:3, 537-544
CrossRef115
Gianni Pezzoli, Michela Zini. (2010) Levodopa in Parkinson's disease: from the past to the future. Expert Opinion on Pharmacotherapy 11:4, 627-635
CrossRef116
Z. Hong, M. Shi, K. A. Chung, J. F. Quinn, E. R. Peskind, D. Galasko, J. Jankovic, C. P. Zabetian, J. B. Leverenz, G. Baird, T. J. Montine, A. M. Hancock, H. Hwang, C. Pan, J. Bradner, U. J. Kang, P. H. Jensen, J. Zhang. (2010) DJ-1 and -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133:3, 713-726
CrossRef117
Elisaveta Milusheva, Mária Baranyi, Eszter Kormos, Zsuzsanna Hracskó, E. Sylvester Vizi, Beáta Sperlágh. (2010) The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices. Neuropharmacology 58:4-5, 816-825
CrossRef118
Angelo Antonini. (2010) Imaging for early differential diagnosis of parkinsonism. The Lancet Neurology 9:2, 130-131
CrossRef119
Neelam K. Venkataramana, Satish K.V. Kumar, Sudheer Balaraju, Radhika Chemmangattu Radhakrishnan, Abhilash Bansal, Ashish Dixit, Deepthi K. Rao, Madhulita Das, Majahar Jan, Pawan Kumar Gupta, Satish M. Totey. (2010) Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Translational Research 155:2, 62-70
CrossRef120
Gilles Fénelon, Guido Alves. (2010) Epidemiology of psychosis in Parkinson's disease. Journal of the Neurological Sciences 289:1-2, 12-17
CrossRef121
Jacques Darcourt, Jan Booij, Klaus Tatsch, Andrea Varrone, Thierry Borght, Özlem L. Kapucu, Kjell Någren, Flavio Nobili, Zuzana Walker, Koen Laere. (2010) EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging 37:2, 443-450
CrossRef122
Matthias Löhle, Heinz Reichmann. (2010) Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough. Journal of the Neurological Sciences 289:1-2, 104-114
CrossRef123
Masato Asanuma, Ikuko Miyazaki, Francisco J. Diaz-Corrales, Naotaka Kimoto, Yuri Kikkawa, Mika Takeshima, Ko Miyoshi, Miho Murata. (2010) Neuroprotective effects of zonisamide target astrocyte. Annals of Neurology 67:2, 239-249
CrossRef124
Chris C Tang, Kathleen L Poston, Thomas Eckert, Andrew Feigin, Steven Frucht, Mark Gudesblatt, Vijay Dhawan, Martin Lesser, Jean-Paul Vonsattel, Stanley Fahn, David Eidelberg. (2010) Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. The Lancet Neurology 9:2, 149-158
CrossRef125
Klaus Tatsch. (2010) Extrapyramidal Syndromes: PET and SPECT. Neuroimaging Clinics of North America 20:1, 57-68
CrossRef126
Mao Junfeng, Liu Shuangzhen, Qin Wenjuan, Li Fengyun, Wu Xiaoying, Tan Qian. (2010) Levodopa Inhibits the Development of Form-Deprivation Myopia in Guinea Pigs. Optometry and Vision Science 87:1, 53-60
CrossRef127
Hideki Mochizuki. (2010) Treatment and pathogenesis of Parkinson's disease. Rinsho Shinkeigaku 50:9, 623-627
CrossRef128
Stanley Fahn. (2010) Parkinson's disease: 10 years of progress, 1997-2007. Movement Disorders 25:S1, S2-S14
CrossRef129
O. Rascol, N. Fabre, C. Brefel-Courbon, F. Ory-Magne, S. Perez-Lloret. 2010. Dyskinesias. , 350-361.
CrossRef130
Jian Wang, YiLong Ma, ZheMin Huang, BoMin Sun, YiHui Guan, ChuanTao Zuo. (2010) Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson’s disease. Journal of Neurology 257:1, 72-78
CrossRef131
T.S. Voss, B. Ravina. 2010. Neuroprotection in Movement Disorders. , 295-299.
CrossRef132
Kathleen L. Poston, David Eidelberg. (2010) 18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease. PET Clinics 5:1, 55-64
CrossRef133
Kelly E. Lyons, Joseph H. Friedman, Neal Hermanowicz, Stuart H. Isaacson, Robert A. Hauser, Bonnie P. Hersh, Dee E. Silver, James W. Tetrud, Lawrence W. Elmer, Sotirios A. Parashos, Lynn K. Struck, Mark F. Lew, Rajesh Pahwa. (2010) Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects. Clinical Neuropharmacology 33:1, 5-10
CrossRef134
J. Eric Ahlskog. (2010) Seniors with Parkinson's Disease: Initial Medical Treatment. Journal of Clinical Neurology 6:4, 159
CrossRef135
Vladimir S. Kostić. (2009) Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists. Parkinsonism & Related Disorders 15, S71-S75
CrossRef136
Walter Maetzler, Inga Liepelt, Daniela Berg. (2009) Progression of Parkinson's disease in the clinical phase: potential markers. The Lancet Neurology 8:12, 1158-1171
CrossRef137
Werner Poewe, Philipp Mahlknecht. (2009) The clinical progression of Parkinson's disease. Parkinsonism & Related Disorders 15, S28-S32
CrossRef138
Robert A. Hauser. (2009) New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategy. Parkinsonism & Related Disorders 15, S17-S21
CrossRef139
H. Nissinen, M. Kuoppamäki, M. Leinonen, A. H. Schapira. (2009) Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinsonâs disease: a long-term, retrospective analysis. European Journal of Neurology 16:12, 1305-1311
CrossRef140
Nicola Pavese, Lorenzo Kiferle, Paola Piccini. (2009) Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism & Related Disorders 15, S33-S37
CrossRef141
Pedro Chaná. (2009) Avances en tratamiento medico de la enfermedad de Parkinson [Advances in the medical treatment of Parkinson's disease]. Parkinsonism & Related Disorders 15, S22-S25
CrossRef142
Nancy L Diaz, Cheryl H Waters. (2009) Current strategies in the treatment of Parkinson’s disease and a personalized approach to management. Expert Review of Neurotherapeutics 9:12, 1781-1789
CrossRef143
M. Angela Cenci, K. Elisabet Ohlin, Daniella Rylander. (2009) Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism & Related Disorders 15, S59-S63
CrossRef144
Stefan Albrecht, Erich Buerger. (2009) Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Current Medical Research and Opinion 25:12, 2977-2987
CrossRef145
Seung-Heon Yoon, D. Bruce Fulton, John F. Robyt. (2009) Synthesis of dopamine and l-DOPA-α-glycosides by reaction with cyclomaltohexaose catalyzed by cyclomaltodextrin glucanyltransferase. Carbohydrate Research 344:17, 2349-2356
CrossRef146
Jin Young Shin, Hyun-Jung Park, Young Hwan Ahn, Phil Hyu Lee. (2009) Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson’s disease: a direct comparison study. Journal of Neurochemistry 111:4, 1042-1050
CrossRef147
Livia Dézsi, László Vécsei. (2009) Established therapies and novel targets in the treatment of Parkinson’s disease. Expert Review of Clinical Pharmacology 2:6, 631-644
CrossRef148
B. Jarraya, S. Boulet, G. Scott Ralph, C. Jan, G. Bonvento, M. Azzouz, J. E. Miskin, M. Shin, T. Delzescaux, X. Drouot, A.-S. Herard, D. M. Day, E. Brouillet, S. M. Kingsman, P. Hantraye, K. A. Mitrophanous, N. D. Mazarakis, S. Palfi. (2009) Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia. Science Translational Medicine 1:2, 2ra4-2ra4
CrossRef149
Joel S. Perlmutter. 2009. Assessment of Parkinson Disease Manifestations. .
CrossRef150
Francesca R. Buttarelli, Gabriela Capriotti, Clelia Pellicano, Daniela Prosperi, Annapia Circella, Anna Festa, Morena Giovannelli, Anna Tofani, Francesco E. Pontieri, Francesco Scopinaro. (2009) Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurological Research 31:7, 687-691
CrossRef151
A. H. V. Schapira, M. Emre, P. Jenner, W. Poewe. (2009) Levodopa in the treatment of Parkinson’s disease. European Journal of Neurology 16:9, 982-989
CrossRef152
Venkatesh Atul Bhattaram, Ohidul Siddiqui, Leonard P. Kapcala, Jogarao V. S. Gobburu. (2009) Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease. The AAPS Journal 11:3, 456-464
CrossRef153
C. Marin, E. Aguilar, G. Mengod, R. Cortés, J. A. Obeso. (2009) Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. European Journal of Neuroscience 30:5, 823-832
CrossRef154
J. G. Kalf, B. J. M. Swart, G. F. Borm, B. R. Bloem, M. Munneke. (2009) Prevalence and definition of drooling in Parkinson’s disease: a systematic review. Journal of Neurology 256:9, 1391-1396
CrossRef155
Un Jung Kang. (2009) Biomarkers in neuropsychiatric diseases. Neurobiology of Disease 35:2, 115-116
CrossRef156
Kathleen L. Poston, David Eidelberg. (2009) Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiology of Disease 35:2, 141-147
CrossRef157
Mark Stacy. (2009) Medical Treatment of Parkinson Disease. Neurologic Clinics 27:3, 605-631
CrossRef158
Berend Arnold Ploeger, Nicholas H. G. Holford. (2009) Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharmaceutical Statistics 8:3, 225-238
CrossRef159
M. Dieterich, G. F. Hamann. (2009) Bericht vom NeuroUpdate der Med-Update-Reihe in Wiesbaden (13./14.02.09). Der Nervenarzt 80:6, 720-724
CrossRef160
Andrew J Lees, John Hardy, Tamas Revesz. (2009) Parkinson's disease. The Lancet 373:9680, 2055-2066
CrossRef161
Myra G. Schneider, Christopher J. Swearingen, Lisa M. Shulman, Jian Ye, Mona Baumgarten, Barbara C. Tilley. (2009) Minority enrollment in Parkinson's disease clinical trials. Parkinsonism & Related Disorders 15:4, 258-262
CrossRef162
E. Ray Dorsey, Joel P. Thompson, Mark Frasier, Todd Sherer, Brian Fiske, Sean Nicholson, S. Claiborne Johnston, Robert G. Holloway, Hamilton Moses. (2009) Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders 24:5, 731-737
CrossRef163
Ikuko Miyazaki, Masato Asanuma. (2009) Approaches to Prevent Dopamine Quinone-Induced Neurotoxicity. Neurochemical Research 34:4, 698-706
CrossRef164
Ivona Brasnjevic, Harry W.M. Steinbusch, Christoph Schmitz, Pilar Martinez-Martinez. (2009) Delivery of peptide and protein drugs over the blood–brain barrier. Progress in Neurobiology 87:4, 212-251
CrossRef165
Rajesh Pahwa, Kelly E. Lyons. (2009) Levodopa-related wearing-off in Parkinson's disease: identification and management. Current Medical Research and Opinion 25:4, 841-849
CrossRef166
Vicky L. Marshall, Cornelia B. Reininger, Moritz Marquardt, Jim Patterson, Donald M. Hadley, Wolfgang H. Oertel, Hani T.S. Benamer, Paul Kemp, David Burn, Eduardo Tolosa, Jamie Kulisevsky, Luis Cunha, Durval Costa, Jan Booij, Klaus Tatsch, K. Ray Chaudhuri, Gudrun Ulm, Oliver Pogarell, Helmut Höffken, Anja Gerstner, Donald G. Grosset. (2009) Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [ 123 I]FP-CIT SPECT. Movement Disorders 24:4, 500-508
CrossRef167
Robert A. Hauser, Michel Panisset, Giovanni Abbruzzese, Linda Mancione, Nalina Dronamraju, Algirdas Kakarieka, . (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorders 24:4, 541-550
CrossRef168
A. Pisani, J. Shen. (2009) Levodopa-induced dyskinesia and striatal signaling pathways. Proceedings of the National Academy of Sciences 106:9, 2973-2974
CrossRef169
Chiung-Mei Chen, Jun-Liang Liu, Yih-Ru Wu, Yi-Chun Chen, Huey-Shinn Cheng, Mei-Ling Cheng, Daniel Tsun-yee Chiu. (2009) Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiology of Disease 33:3, 429-435
CrossRef170
J. Serrano Vicente, L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J.R. Infante de la Torre, M.L. Domínguez Grande, J.I. Rayo Madrid, R. Sánchez Sánchez, C. Durán Herrera. (2009) Valor predictivo negativo del SPECT con Ioflupano 123I en los trastornos del movimiento. Revista Española de Medicina Nuclear 28:1, 2-5
CrossRef171
Anthony H.V. Schapira. (2009) Neurobiology and treatment of Parkinson's disease. Trends in Pharmacological Sciences 30:1, 41-47
CrossRef172
Shin-ichi Ono, Kohji Hirai, Ei-ichi Tokuda. (2009) Effects of Pergolide Mesilate on Metallothionein mRNAs Expression in a Mouse Model for Parkinson Disease. Biological & Pharmaceutical Bulletin 32:10, 1813-1817
CrossRef173
Dean F Wong, Johannes Tauscher, Gerhard Gründer. (2009) The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development. Neuropsychopharmacology 34:1, 187-203
CrossRef174
Jae Seung Kim, Seung Jun Oh, Dae Hyuk Moon. (2009) Molecular Imaging in Neurodegenerative Diseases. Journal of the Korean Medical Association 52:2, 151
CrossRef175
Shigeki Hirano, Thomas Eckert, Toni Flanagan, David Eidelberg. (2009) Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Movement Disorders 24:S2, S725-S731
CrossRef176
Werner Poewe. (2009) Clinical measures of progression in Parkinson's disease. Movement Disorders 24:S2, S671-S676
CrossRef177
Connie Marras, Anthony E. Lang, Shirley W. Eberly, David Oakes, Stanley Fahn, Steven R. Schwid, Christopher Hyson, Ira Shoulson, . (2009) A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Movement DisordersNA-NA
CrossRef178
Edward J. Newman, Kieran Breen, Jim Patterson, Donald M. Hadley, Katherine A. Grosset, Donald G. Grosset. (2009) Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Movement DisordersNA-NA
CrossRef179
Robert A. Hauser, Peggy Auinger, David Oakes, . (2009) Levodopa response in early Parkinson's disease. Movement DisordersNA-NA
CrossRef180
Christoph Scherfler, Michael Nocker. (2009) Dopamine transporter SPECT: How to remove subjectivity?. Movement Disorders 24:S2, S721-S724
CrossRef181
Peter A. LeWitt. (2009) Levodopa therapeutics for Parkinson's disease: new developments. Parkinsonism & Related Disorders 15, S31-S34
CrossRef182
Toshiharu Nagatsu, Makoto Sawada. (2009) L-dopa therapy for Parkinson's disease: Past, present, and future. Parkinsonism & Related Disorders 15, S3-S8
CrossRef183
Nobutaka Hattori, Mei Wang, Hikari Taka, Tsutomu Fujimura, Asako Yoritaka, Shin-ichiro Kubo, Hideki Mochizuki. (2009) Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism & Related Disorders 15, S35-S38
CrossRef184
Miho Murata. (2009) Levodopa in the early treatment of Parkinson's disease. Parkinsonism & Related Disorders 15, S17-S20
CrossRef185
LeWitt, Peter A., . (2008) Levodopa for the Treatment of Parkinson's Disease. New England Journal of Medicine 359:23, 2468-2476
Full Text186
Francisco J. Diaz-Corrales, Masato Asanuma, Ikuko Miyazaki, Ko Miyoshi, Nobutaka Hattori, Norio Ogawa. (2008) Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells. Neurotoxicity Research 14:4, 295-305
CrossRef187
Maria Hadjiconstantinou, Norton H. Neff. (2008) Enhancing Aromatic L-amino Acid Decarboxylase Activity: Implications for L-DOPA Treatment in Parkinson's Disease. CNS Neuroscience & Therapeutics 14:4, 340-351
CrossRef188
Jose A. Obeso, Concepcio Marin, C. Rodriguez-Oroz, Javier Blesa, B. Benitez-Temiño, Juan Mena-Segovia, Manuel Rodríguez, C. Warren Olanow. (2008) The basal ganglia in Parkinson's disease: Current concepts and unexplained observations. Annals of Neurology 64:S2, S30-S46
CrossRef189
Chun Zhou, Yong Huang, Serge Przedborski. (2008) Oxidative Stress in Parkinson's Disease. Annals of the New York Academy of Sciences 1147:1, 93-104
CrossRef190
C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso. (2008) Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. Neurobiology of Disease 32:3, 340-348
CrossRef191
Angelo Antonini, Paolo Barone. (2008) Dopamine agonist-based strategies in the treatment of Parkinson’s disease. Neurological Sciences 29:S5, 371-374
CrossRef192
Anthony H. V. Schapira, C. Warren Olanow. (2008) Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology 64:S2, S47-S55
CrossRef193
Karl Strecker, Johannes Schwarz. (2008) Parkinson's disease: emerging pharmacotherapy. Expert Opinion on Emerging Drugs 13:4, 573-591
CrossRef194
Giovanni Abbruzzese. (2008) Optimising levodopa therapy. Neurological Sciences 29:S5, 377-379
CrossRef195
C. Warren Olanow, Robert A. Hauser, Joseph Jankovic, William Langston, Anthony Lang, Werner Poewe, Eduardo Tolosa, Fabrizio Stocchi, Eldad Melamed, Eli Eyal, Olivier Rascol. (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. Movement Disorders 23:15, 2194-2201
CrossRef196
Roongroj Bhidayasiri, Daniel D. Truong. (2008) Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management. Journal of the Neurological Sciences 273:1-2, 156-157
CrossRef197
Brit Mollenhauer, Valerie Cullen, Ilana Kahn, Bryan Krastins, Tiago F. Outeiro, Imelda Pepivani, Juliana Ng, Walter Schulz-Schaeffer, Hans A. Kretzschmar, Pamela J. McLean, Claudia Trenkwalder, David A. Sarracino, Jean-Paul VonSattel, Joseph J. Locascio, Omar M.A. El-Agnaf, Michael G. Schlossmacher. (2008) Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology 213:2, 315-325
CrossRef198
Christopher D Herzog, Biplob Dass, Mehdi Gasmi, Roy Bakay, James E Stansell, Mark Tuszynski, Krystof Bankiewicz, Er-Yun Chen, Yaping Chu, Kathie Bishop, Jeffrey H Kordower, Raymond T Bartus. (2008) Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum. Molecular Therapy 16:10, 1737-1744
CrossRef199
Heinz Reichmann. (2008) Initiation of Parkinson’s disease treatment. Journal of Neurology 255:S5, 57-59
CrossRef200
Thomas D. Hälbig, Ute A. Kopp, Franziska Wodarz, Joan C. Borod, Jean-Michel Gracies, Georg Ebersbach, Andreas Kupsch. (2008) Dopaminergic modulation of emotional memory in Parkinson’s disease. Journal of Neural Transmission 115:8, 1159-1163
CrossRef201
Tjitske A Boonstra, Herman van der Kooij, Marten Munneke, Bastiaan R Bloem. (2008) Gait disorders and balance disturbances in Parkinsonʼs disease: clinical update and pathophysiology. Current Opinion in Neurology 24:4, 461-471
CrossRef202
Dee E. Silver. (2008) Early, Nondisabling Parkinson's Disease: Weighing the Options for Initial Therapy. Neurologic Clinics 26:3, 1-13
CrossRef203
Tiffini Voss, Bernard Ravina. (2008) Neuroprotection in Parkinson’s disease: Myth or reality?. Current Neurology and Neuroscience Reports 8:4, 304-309
CrossRef204
Murray Hong, Karim Mukhida, Ivar Mendez. (2008) GDNF therapy for Parkinson’s disease. Expert Review of Neurotherapeutics 8:7, 1125-1139
CrossRef205
Arianna Bellucci, Ginetta Collo, Ilenia Sarnico, Leontino Battistin, Cristina Missale, PierFranco Spano. (2008) Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D 2 D 3 receptor activation. Journal of Neurochemistry 106:2, 560-577
CrossRef206
P. Damier, F. Viallet, M. Ziegler, I. Bourdeix, K. Rerat. (2008) Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. European Journal of Neurology 15:7, 643-648
CrossRef207
David B. Sommer, Larry B. Goldstein. 2008. Central Nervous System (CNS). .
CrossRef208
Thomas Müller. (2008) Role of homocysteine in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics 8:6, 957-967
CrossRef209
John Nutt. (2008) Reply: Continuous stimulation: Is it the answer to the motor complications of levodopa. Movement Disorders 23:7, 1063-1063
CrossRef210
H. Förstl. (2008) Behandlungs- und Versorgungsstrategien bei Alzheimer und verwandten Demenzen. Der Nervenarzt 79:5, 617-629
CrossRef211
Carl E. Clarke. (2008) Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?. Movement Disorders 23:6, 784-789
CrossRef212
Rebecca Stowe, Natalie Ives, Carl E Clarke, van Hilten, Joaquim Ferreira, Robert J Hawker, Laila Shah, Keith Wheatley, Richard Gray, Rebecca Stowe. 2008. Dopamine agonist therapy in early Parkinson's disease. .
CrossRef213
Christopher G. Goetz, Joanne Wuu, Michael P. McDermott, Charles H. Adler, Stanley Fahn, Curt R. Freed, Robert A. Hauser, Warren C. Olanow, Ira Shoulson, P.K. Tandon, , Sue Leurgans. (2008) Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Movement Disorders 23:5, 690-699
CrossRef214
Jon Stoessl. (2008) Potential therapeutic targets for Parkinson's disease. Expert Opinion on Therapeutic Targets 12:4, 425-436
CrossRef215
Mitsutoshi Yamamoto, Anthony HV Schapira. (2008) Dopamine agonists in Parkinson’s disease. Expert Review of Neurotherapeutics 8:4, 671-677
CrossRef216
A. H. V. Schapira. (2008) Progress in neuroprotection in Parkinson’s disease. European Journal of Neurology 15:s1, 5-13
CrossRef217
Peter A. LeWitt, Danette C. Taylor. (2008) Protection against Parkinson’s disease progression: Clinical experience. Neurotherapeutics 5:2, 210-225
CrossRef218
Stewart A. Factor. (2008) Current status of symptomatic medical therapy in Parkinson’s disease. Neurotherapeutics 5:2, 164-180
CrossRef219
Masako Shimizu, Ikuko Miyazaki, Youichirou Higashi, Maria J. Eslava-Alva, Francisco J. Diaz-Corrales, Masato Asanuma, Norio Ogawa. (2008) Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats. Neuroscience Research 60:4, 355-363
CrossRef220
Rachel Saunders-Pullman, Carol Derby, Kaili Stanley, Alicia Floyd, Susan Bressman, Richard B. Lipton, Amanda Deligtisch, Lawrence Severt, Qiping Yu, Mónica Kurtis, Seth L. Pullman. (2008) Validity of spiral analysis in early Parkinson's disease. Movement Disorders 23:4, 531-537
CrossRef221
H. Förstl. (2008) Antidementiva – wem nützen sie wirklich?. Der Internist 49:3, 353-359
CrossRef222
Roongroj Bhidayasiri, Daniel D. Truong. (2008) Motor complications in Parkinson disease: Clinical manifestations and management. Journal of the Neurological Sciences 266:1-2, 204-215
CrossRef223
W. R. Wayne Martin, Marguerite Wieler, A. Jon Stoessl, Michael Schulzer. (2008) Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Annals of Neurology 63:3, 388-394
CrossRef224
Sven E. Pålhagen, Esa Heinonen. (2008) Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson's Disease: Perspectives from the MONOCOMB Study. Progress in Neurotherapeutics and Neuropsychopharmacology 3:01,
CrossRef225
X. Zhang, P. E. Andren, P. Greengard, P. Svenningsson. (2008) Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proceedings of the National Academy of Sciences 105:6, 2163-2168
CrossRef226
Jan Booij, Paul Kemp. (2008) Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. European Journal of Nuclear Medicine and Molecular Imaging 35:2, 424-438
CrossRef227
Barbara Picconi, Vincent Paillé, Veronica Ghiglieri, Vincenza Bagetta, Ilaria Barone, Hanna S. Lindgren, Giorgio Bernardi, M. Angela Cenci, Paolo Calabresi. (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiology of Disease 29:2, 327-335
CrossRef228
Paul S. Fishman. (2008) Paradoxical aspects of parkinsonian tremor. Movement Disorders 23:2, 168-173
CrossRef229
Maria Teresa Pellecchia, Katia Longo, Michela Manfredi, Claudio Lucetti, Giovanni Cossu, Alfredo Petrone, Roberto Marconi, Mariachiara Sensi, Antonio Epifanio, Roberto Eleopra, Roberta Marchese, Tomaso Scaravilli, Letterio Morgante, Giovanni Abbruzzese, Ubaldo Bonuccelli, Edoardo Donati, Rosario Pivonello, Annamaria Colao, Paolo Barone. (2008) The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Movement Disorders 23:2, 190-194
CrossRef230
S. Crotty, P. Fitzgerald, E. Tuohy, D. M. Harris, A. Fisher, A. Mandel, A. E. Bolton, A. M. Sullivan, Y. Nolan. (2008) Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease. European Journal of Neuroscience 27:2, 294-300
CrossRef231
Aabha Sharma, Pushpinder Kaur, Binu Kumar, S. Prabhakar, K.D. Gill. (2008) Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. Parkinsonism & Related Disorders 14:1, 52-57
CrossRef232
Nir Giladi. (2008) Medical treatment of freezing of gait. Movement Disorders 23:S2, S482-S488
CrossRef233
C. Warren Olanow. (2008) Levodopa/dopamine replacement strategies in Parkinson's disease-Future directions. Movement Disorders 23:S3, S613-S622
CrossRef234
Miho Murata. (2008) Therapy of Parkinson's disease-up to date. Rinsho Shinkeigaku 48:11, 986-988
CrossRef235
Miho Murata. (2008) The development of therapeutic agents for Parkinson's disease and problems in their clinical application. Folia Pharmacologica Japonica 131:4, 281-284
CrossRef236
Travis B. Lewis, David G. Standaert. (2008) Design of clinical trials of gene therapy in Parkinson disease. Experimental Neurology 209:1, 41-47
CrossRef237
Hervé Allain, Danièle Bentué-Ferrer, Yvette Akwa. (2008) Disease-modifying drugs and Parkinson's disease. Progress in Neurobiology 84:1, 25-39
CrossRef238
Fabrizio Stocchi, Michele Tagliati, C. Warren Olanow. (2008) Treatment of levodopa-induced motor complications. Movement Disorders 23:S3, S599-S612
CrossRef239
Anthony H.V. Schapira. (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Movement Disorders 23:S3, S515-S520
CrossRef240
Stanley Fahn. (2008) The history of dopamine and levodopa in the treatment of Parkinson's disease. Movement Disorders 23:S3, S497-S508
CrossRef241
Susan H. Fox, Anthony E. Lang. (2008) Levodopa-related motor complications-Phenomenology. Movement Disorders 23:S3, S509-S514
CrossRef242
C. Warren Olanow, Andrew Lees, Jose Obeso. (2008) Levodopa therapy for Parkinson's disease: Challenges and future prospects. Movement Disorders 23:S3, S495-S496
CrossRef243
John G. Nutt. (2008) Pharmacokinetics and pharmacodynamics of levodopa. Movement Disorders 23:S3, S580-S584
CrossRef244
Jack J Chen, David M Swope. (2007) Pharmacotherapy for Parkinson's Disease. Pharmacotherapy 27:12 Part 2, 161S-173S
CrossRef245
Mark Lew. (2007) Overview of Parkinson's Disease. Pharmacotherapy 27:12 Part 2, 155S-160S
CrossRef246
Micaela Morelli, Therese Di Paolo, Jadwiga Wardas, Frederic Calon, Danqing Xiao, Michael A. Schwarzschild. (2007) Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Progress in Neurobiology 83:5, 293-309
CrossRef247
Mario Di Napoli, Imtiaz M Shah, David A Stewart. (2007) Molecular pathways and genetic aspects of Parkinson’s disease: from bench to bedside. Expert Review of Neurotherapeutics 7:12, 1693-1729
CrossRef248
Peter Riederer, Manfred Gerlach, Thomas Müller, Heinz Reichmann. (2007) Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease. Parkinsonism & Related Disorders 13:8, 466-479
CrossRef249
M. Steiger. (2007) Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease. European Journal of Neurology 0:0, 071203214007012-???
CrossRef250
Miguel Coelho, Joaquim Ferreira, Cristina Sampaio. 2007. Parkinson's Disease. , 199-220.
CrossRef251
John P. Seibyl, Wei Chen, Daniel H.S. Silverman. (2007) 3,4-Dihydroxy-6-[18F]-Fluoro-L-Phenylalanine Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors. Seminars in Nuclear Medicine 37:6, 440-450
CrossRef252
T. Müller, L. Ander, K. Kolf, D. Woitalla, S. Muhlack. (2007) Comparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease. Journal of Neural Transmission 114:11, 1457-1462
CrossRef253
Diego Centonze, Giorgio Bernardi, Giacomo Koch. (2007) Mechanisms of Disease: basic-research-driven investigations in humans—the case of hyperkinetic disorders. Nature Clinical Practice Neurology 3:10, 572-580
CrossRef254
Nirit Lev, Ruth Djaldetti, Eldad Melamed. (2007) Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa. Journal of Neurology 254:S5, 19-26
CrossRef255
Yoshikuni Mizuno. (2007) Where do we stand in the treatment of Parkinson's disease?. Journal of Neurology 254:S5, 13-18
CrossRef256
Kazuko Hasegawa. (2007) Parkinson's Disease Treatment Guidelines 2002 issued by Societas Neurologica Japonica. Journal of Neurology 254:S5, 8-12
CrossRef257
Kenichi Kashihara. (2007) Management of levodopa-induced dyskinesias in Parkinson's disease. Journal of Neurology 254:S5, 27-31
CrossRef258
Emilie Lacombe, Carole Carcenac, Sabrina Boulet, Claude Feuerstein, Anne Bertrand, Annie Poupard, Marc Savasta. (2007) High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. European Journal of Neuroscience 26:6, 1670-1680
CrossRef259
William G. Ondo, Kapil D. Sethi, Greg Kricorian. (2007) Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms. Clinical Neuropharmacology 30:5, 295-300
CrossRef260
Günther Deuschl, Antanas Vaitkus, Gabriele-Cornelia Fox, Torsten Roscher, Dieter Schremmer, Ariel Gordin, . (2007) Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Movement Disorders 22:11, 1550-1555
CrossRef261
Walter Koch, Mona Mustafa, Christian Zach, Klaus Tatsch. (2007) Influence of movement on FP-CIT SPECT quantification: a Monte Carlo based simulation. Nuclear Medicine Communications 28:8, 603-614
CrossRef262
Albert Y Hung, Michael A Schwarzschild. (2007) Clinical trials for neuroprotection in Parkinson??s disease: overcoming angst and futility?. Current Opinion in Neurology 20:4, 477-483
CrossRef263
Ronald F Pfeiffer. (2007) Transdermal drug delivery in Parkinson’s disease. Aging Health 3:4, 471-482
CrossRef264
T. Müller, D. Woitalla, H. Russ, K. Hock, D. A. Haeger. (2007) Prevalence and treatment strategies of dyskinesia in patients with Parkinson’s disease. Journal of Neural Transmission 114:8, 1023-1026
CrossRef265
Giovanni Fabbrini, Jonathan M. Brotchie, Francisco Grandas, Masahiro Nomoto, Christopher G. Goetz. (2007) Levodopa-induced dyskinesias. Movement Disorders 22:10, 1379-1389
CrossRef266
Christoph Scherfler, Johannes Schwarz, Angelo Antonini, Donald Grosset, Francesc Valldeoriola, Kenneth Marek, Wolfgang Oertel, Eduardo Tolosa, Andrew J. Lees, Werner Poewe. (2007) Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Movement Disorders 22:9, 1229-1238
CrossRef267
Radu Constantinescu, Megan Romer, Michael P. McDermott, Cornelia Kamp, Karl Kieburtz, . (2007) Impact of pramipexole on the onset of levodopa-related dyskinesias. Movement Disorders 22:9, 1317-1319
CrossRef268
Theresa A. Zesiewicz, Kelly L. Sullivan, Robert A. Hauser. (2007) Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment. Current Neurology and Neuroscience Reports 7:4, 302-310
CrossRef269
Kelly E. Lyons, Rajesh Pahwa. (2007) Electronic motor function diary for patients with Parkinson's disease: A feasibility study. Parkinsonism & Related Disorders 13:5, 304-307
CrossRef270
Huw R Morris. (2007) Autosomal dominant Parkinson’s disease and the route to new therapies. Expert Review of Neurotherapeutics 7:6, 649-656
CrossRef271
Hubert H. Fernandez, Jack J. Chen. (2007) Monamine Oxidase Inhibitors. Clinical Neuropharmacology 30:3, 150-168
CrossRef272
Robert A. Hauser, Theresa A. Zesiewicz. (2007) Advances in the Pharmacologic Management of Early Parkinson Disease. The Neurologist 13:3, 126-132
CrossRef273
B DEGIRMENCI, M YAMAN, A HAKTANIR, R ALBAYRAK, M ACAR, G CALISKAN. (2007) The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease. Neuroscience Letters 416:3, 294-298
CrossRef274
Charlene Hoffman Snyder, Charles H. Adler. (2007) The patient with Parkinson?s disease: Part I?Treating the motor symptoms; Part II?Treating the nonmotor symptoms. Journal of the American Academy of Nurse Practitioners 19:4, 179-197
CrossRef275
Kurt Samson. (2007) Prolonged-Release Ropinirole for PD Found Effective in Large Clinical Trial. Neurology Today 7:7, 9,10
CrossRef276
Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford. (2007) Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation. Pharmaceutical Research 24:4, 791-802
CrossRef277
Dieter Scheller, Piu Chan, Qin Li, Tao Wu, Renling Zhang, Le Guan, Paula Ravenscroft, Celine Guigoni, Alan R. Crossman, Michael Hill, Erwan Bezard. (2007) Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Experimental Neurology 203:2, 415-422
CrossRef278
Thomas Eckert, Andrew Feigin, Daniel E. Lewis, Vijay Dhawan, Steven Frucht, David Eidelberg. (2007) Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging. Movement Disorders 22:2, 167-173
CrossRef279
Jack J Chen, Hubert H Fernandez. (2007) Community and Long-Term Care Management of Parkinson???s Disease in the Elderly. Drugs & Aging 24:8, 663-680
CrossRef280
Irene A C Halkias, Ihtsham Haq, Zhigao Huang, Hubert H Fernandez. (2007) When Should Levodopa Therapy be Initiated in Patients with Parkinson??s Disease?. Drugs & Aging 24:4, 261-273
CrossRef281
Hubert H Fernandez, Jack J Chen. (2007) Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease. Pharmacotherapy 27:12part2, 174S
CrossRef282
C. Marin, E. Aguilar, G. Mengod, R. Cortés, J. A. Obeso. (2007) Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. European Journal of Neuroscience 25:1, 259-269
CrossRef283
John G. Nutt. (2007) Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?. Movement Disorders 22:1, 1-9
CrossRef284
Anthony H.V. Schapira. (2007) Future directions in the treatment of Parkinson's disease. Movement Disorders 22:S17, S385-S391
CrossRef285
David J. Brooks. (2007) Assessment of Parkinson's disease with imaging. Parkinsonism & Related Disorders 13, S268-S275
CrossRef286
Jeffrey H. Kordower, Christopher D. Herzog, Biplob Dass, Roy A. E. Bakay, James Stansell, Mehdi Gasmi, Raymond T. Bartus. (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology 60:6, 706-715
CrossRef287
Vicky L. Marshall, Jim Patterson, Donald M. Hadley, Katherine A. Grosset, Donald G. Grosset. (2006) Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nuclear Medicine Communications 27:12, 933-937
CrossRef288
Werner Poewe. (2006) The natural history of Parkinson’s disease. Journal of Neurology 253:S7, vii2-vii6
CrossRef289
Astrid Thomas, Laura Bonanni, Angelo Di Iorio, Sara Varanese, Francesca Anzellotti, Anna D’Andreagiovanni, Fabrizio Stocchi, Marco Onofrj. (2006) End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson’s disease. Journal of Neurology 253:12, 1633-1639
CrossRef290
Anthony E Lang. (2006) Neuroprotection in Parkinson's disease: and now for something completely different?. The Lancet Neurology 5:12, 990-991
CrossRef291
Vicky L. Marshall, Jim Patterson, Donald M. Hadley, Katherine A. Grosset, Donald G. Grosset. (2006) Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Movement Disorders 21:12, 2247-2250
CrossRef292
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society?European Section. Part I: early (uncomplicated) Parkinson's disease. European Journal of Neurology 13:11, 1170-1185
CrossRef293
Mark Stacy, Robert Hauser, Wolfgang Oertel, Anthony Schapira, Kapil Sethi, Fabrizio Stocchi, Eduardo Tolosa. (2006) End-of-dose Wearing Off in Parkinson Disease. Clinical Neuropharmacology 29:6, 312-321
CrossRef294
Maria Teresa Pellecchia, Katia Longo, Rosario Pivonello, Claudio Lucetti, Roberta Marchese, Annalisa Spampani, Michela Manfredi, Antonio Epifanio, Mariachiara Sensi, Tomaso Scaravilli, Fulvio Bracco, Roberto Eleopra, Letterio Morgante, Edoardo Donati, Roberto Marconi, Giovanni Abbruzzese, Ubaldo Bonuccelli, Mario Zappia, Annamaria Colao, Paolo Barone. (2006) Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. Annals of Neurology 60:5, 611-615
CrossRef295
William J Weiner. (2006) Levodopa—toxic or neuroprotective?. Nature Clinical Practice Neurology 2:10, 518-519
CrossRef296
Thomas Müller. (2006) Tolcapone in the management of Parkinson’s disease. Aging Health 2:5, 709-720
CrossRef297
T. Müller, C. Erdmann, S. Muhlack, D. Bremen, H. Przuntek, O. Goetze, D. Woitalla. (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. Journal of Neural Transmission 113:10, 1441-1448
CrossRef298
Heinz Reichmann, Anja Bilsing, Reinhard Ehret, Wolfgang Greulich, Jörg B. Schulz, Andreas Schwartz, Olivier Rascol. (2006) Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease. Journal of Neurology 253:S4, iv36-iv38
CrossRef299
Masato Asanuma, Ikuko Miyazaki. (2006) Nonsteroidal anti-inflammatory drugs in Parkinson’s disease: possible involvement of quinone formation. Expert Review of Neurotherapeutics 6:9, 1313-1325
CrossRef300
G. Gille, K. Radad, H. Reichmann, W.-D. Rausch. (2006) Synergistic effect of α-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. Journal of Neural Transmission 113:9, 1107-1118
CrossRef301
Kenichi Sato, Taku Hatano, Kazuo Yamashiro, Maki Kagohashi, Kenya Nishioka, Nana Izawa, Hideki Mochizuki, Nobutaka Hattori, Hideo Mori, Yoshikuni Mizuno, . (2006) Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations. Movement Disorders 21:9, 1384-1395
CrossRef302
Thomas Müller, Hermann Russ. (2006) Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opinion on Pharmacotherapy 7:13, 1715-1730
CrossRef303
N.P. Visanji, M.J. O'Neill, S. Duty. (2006) Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51:3, 506-516
CrossRef304
Kazuki Kobayashi, Takao Yasuhara, Takashi Agari, Kenichiro Muraoka, Masahiro Kameda, wen Ji Yuan, Hitoshi Hayase, Toshihiro Matsui, Yasuyuki Miyoshi, Tetsuro Shingo, Isao Date. (2006) Control of dopamine-secretion by Tet-Off system in an in vivo model of parkinsonian rat. Brain Research 1102:1, 1-11
CrossRef305
Alan Diamond, Joseph Jankovic. (2006) Treatment of advanced Parkinson’s disease. Expert Review of Neurotherapeutics 6:8, 1181-1197
CrossRef306
Anette Schrag, Cristina Sampaio, Nicholas Counsell, Werner Poewe. (2006) Minimal clinically important change on the unified Parkinson's disease rating scale. Movement Disorders 21:8, 1200-1207
CrossRef307
Fabrizio Stocchi. (2006) The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opinion on Pharmacotherapy 7:10, 1399-1407
CrossRef308
Dee Silver. (2006) Impact of Functional Age on the Use of Dopamine Agonists in Patients With Parkinson Disease. The Neurologist 12:4, 214-223
CrossRef309
C Warren Olanow, José A Obeso, Fabrizio Stocchi. (2006) Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clinical Practice Neurology 2:7, 382-392
CrossRef310
Alessandro Prigione, Barbara Begni, Alessio Galbussera, Simone Beretta, Laura Brighina, Rosanna Garofalo, Simona Andreoni, Roberto Piolti, Carlo Ferrarese. (2006) Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: Negative correlation with levodopa dosage. Neurobiology of Disease 23:1, 36-43
CrossRef311
Ulrich Raff, Michael Hutchinson, Gonzalo M. Rojas, Isidro Huete. (2006) Inversion Recovery MRI in Idiopathic Parkinson Disease Is a Very Sensitive Tool to Assess Neurodegeneration in the Substantia Nigra. Academic Radiology 13:6, 721-727
CrossRef312
Spiridon Konitsiotis, Christos Tsironis. (2006) Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: Independent features or components of the same phenomenon?. Behavioural Brain Research 170:2, 337-341
CrossRef313
E Ray Dorsey, Robert G Holloway, Bernard M Ravina. (2006) Biomarkers in Parkinson’s disease. Expert Review of Neurotherapeutics 6:6, 823-831
CrossRef314
Daniel Tarsy. (2006) Initial treatment of parkinson’s disease. Current Treatment Options in Neurology 8:3, 224-235
CrossRef315
Kelly E. Lyons, Rajesh Pahwa. (2006) Efficacy and Tolerability of Levetiracetam in Parkinson Disease Patients With Levodopa-Induced Dyskinesia. Clinical Neuropharmacology 29:3, 148-153
CrossRef316
Brad A. Racette, Laura Good, Jo Ann Antenor, Lori McGee-Minnich, Stephen M. Moerlein, Tom O. Videen, Joel S. Perlmutter. (2006) [18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 141B:3, 245-249
CrossRef317
Hatasu Kobayashi, Shinji Oikawa, Shosuke Kawanishi. (2006) Mechanism of DNA Damage and Apoptosis Induced by Tetrahydropapaveroline, a Metabolite of Dopamine. Neurochemical Research 31:4, 523-532
CrossRef318
Kelly E. Lyons, Rajesh Pahwa. (2006) Conversion From Sustained Release Carbidopa/Levodopa to Carbidopa/Levodopa/Entacapone (Stalevo) in Parkinson Disease Patients. Clinical Neuropharmacology 29:2, 73-76
CrossRef319
Yuri Bozzi, Emiliana Borrelli. (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends in Neurosciences 29:3, 167-174
CrossRef320
Sandrine Benaderette, Paolo Zanotti Fregonara, Emmanuelle Apartis, Charles Nguyen, Jean-Marc Trocello, Philippe Remy, Jean-Yves Devaux, Serge Askienazy, Marie Vidailhet. (2006) Psychogenic parkinsonism: A combination of clinical, electrophysiological, and [123I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Movement Disorders 21:3, 310-317
CrossRef321
Anthony H. V. Schapira, Jose Obeso. (2006) Timing of treatment initiation in Parkinson's disease: A need for reappraisal?. Annals of Neurology 59:3, 559-562
CrossRef322
Michael J. Aminoff. (2006) Treatment should not be initiated too soon in Parkinson's disease. Annals of Neurology 59:3, 562-564
CrossRef323
John T Slevin, Melody Ryan. (2006) Orally disintegrating carbidopa/levodopa. Future Neurology 1:2, 139-147
CrossRef324
Wolfgang H. Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Max Dujardin, Donald G. Grosset, Guy Arnold, Klaus L. Leenders, Hans-Peter Hundemer, Alberto Lledó, Andrew Wood, Paul Frewer, Johannes Schwarz. (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Movement Disorders 21:3, 343-353
CrossRef325
Thomas Müller, Christoph Erdmann, Siegfried Muhlack, Dirk Bremen, Horst Przuntek, Dirk Woitalla. (2006) Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Movement Disorders 21:3, 332-336
CrossRef326
Francisco Grandas. (2006) Levodopa for the treatment of Parkinson’s disease: current perspectives. Aging Health 2:1, 101-109
CrossRef327
Felix Geser, Gregor K. Wenning, Klaus Seppi, Michaela Stampfer-Kountchev, Christoph Scherfler, Martin Sawires, Carolin Frick, Jean-Pierre Ndayisaba, Hanno Ulmer, Maria T. Pellecchia, Paolo Barone, Hee T. Kim, Juzar Hooker, Niall P. Quinn, Adriana Cardozo, Eduardo Tolosa, Michael Abele, Thomas Klockgether, Karen Østergaard, Erik Dupont, Nicole Schimke, Karla M. Eggert, Wolfgang Oertel, Ruth Djaldetti, Werner Poewe, . (2006) Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). Movement Disorders 21:2, 179-186
CrossRef328
Nicolaas I Bohnen, Roger L Albin, Robert A Koeppe, Kristine A Wernette, Michael R Kilbourn, Satoshi Minoshima, Kirk A Frey. (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. Journal of Cerebral Blood Flow & Metabolism
CrossRef329
Lorenzo Priano, Maria Rosa Gasco, Alessandro Mauro. (2006) Transdermal Treatment Options for Neurological Disorders. Drugs & Aging 23:5, 357-375
CrossRef330
Ubaldo Bonuccelli, Nicola Pavese. (2006) Dopamine agonists in the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 6:1, 81-89
CrossRef331
Orazio Schillaci, Mariangela Pierantozzi, Luca Filippi, Carlo Manni, Livia Brusa, Roberta Danieli, Giorgio Bernardi, Giovanni Simonetti, Paolo Stanzione. (2005) The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. European Journal of Nuclear Medicine and Molecular Imaging 32:12, 1452-1456
CrossRef332
Tomoyoshi Kondo. (2005) Levodopa therapy from the neuroprotection viewpoint. Journal of Neurology 252:S4, iv32-iv36
CrossRef333
Stanley Fahn, . (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease?. Journal of Neurology 252:S4, iv37-iv42
CrossRef334
Fabrizio Stocchi. (2005) Optimising levodopa therapy for the management of Parkinson’s disease. Journal of Neurology 252:S4, iv43-iv48
CrossRef335
Nutt, John G., Wooten, G. Frederick, . (2005) Diagnosis and Initial Management of Parkinson's Disease. New England Journal of Medicine 353:10, 1021-1027
Full Text336
&NA;. (2005) 2005–2006 MEETING PLANNER. Neurology Today 5:8, 55-56
CrossRef337
Juan A. Burguera Hernández. (2005) Neuroimagen en los trastornos del movimiento. Revista Española de Medicina Nuclear 24:4, 221-223
CrossRef338
Brian J Snyder, C Warren Olanow. (2005) Stem cell treatment for Parkinsonʼs disease: an update for 2005. Current Opinion in Neurology 18:4, 376-385
CrossRef339
Richard Robinson. (2005) STUDY EXAMINES ROLE OF IMAGING IN DIAGNOSING PARKINSON DISEASE. Neurology Today 5:8, 47-48
CrossRef340
Thomas Eckert, Anna Barnes, Vijay Dhawan, Steve Frucht, Mark F. Gordon, Andrew S. Feigin, D. Eidelberg. (2005) FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 26:3, 912-921
CrossRef341
Sheila A Doggrell. (2005) Recent important trials of pharmacotherapy in Parkinson’s disease. Expert Opinion on Pharmacotherapy 6:6, 1025-1028
CrossRef342
Mahyar Etminan, Sudeep S Gill, Ali Samii. (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. The Lancet Neurology 4:6, 362-365
CrossRef343
Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen. (2005) Treatment of motor dysfunction in Parkinson's disease: an overview. Clinical Neurology and Neurosurgery 107:4, 269-281
CrossRef344
Donald Calne, Michael Schulzer, Edwin Mak, A Jon Stoessl. (2005) Treatment for the progression of Parkinson's disease. The Lancet Neurology 4:4, 206
CrossRef345
Thomas Eckert, David Eidelberg. (2005) Neuroimaging and therapeutics in movement disorders. NeuroRX 2:2, 361-371
CrossRef346
(2005) Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine 352:13, 1386-1386
Full Text347
Michel Dib. (2005) Issues for Clinical Drug Development in Neurodegenerative Diseases. Drugs 65:17, 2463-2479
CrossRef348
Thomas Eckert, David Eidelberg. (2005) Neuroimaging and therapeutics in movement disorders. NeuroRX 2:2, 361
CrossRef349
William Lin, Un Jung Kang. (2005) Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues. Journal of Clinical Neurology 1:2, 107
CrossRef350
Press, Daniel Z., . (2004) Parkinson's Disease Dementia — A First Step?. New England Journal of Medicine 351:24, 2547-2549
Full Text
- Letters
